In vivo Testing of Nanotherapeutics for Osteosarcoma Treatment: Translational Challenges and Solutions Authors: Gabriele D’Anna, Endris Yibru Hanurry, Anna Piperno, Angela Scala Published: 2025 ABSTRACT AbstractOsteosarcoma (OS) is a malignant bone tumor primarily affecting children and teenagers, characterized by aggressiveness and early metastasis especially to the lungs. OS management is complex and combined-modality therapy involving surgery, chemotherapy and immunotherapy is common. The standard care treatment utilizing doxorubicin, cisplatin, and high-dose methotrexate is a combination (“MAP”) not changed in more than 40 years that often confronts incomplete tumor removal, recurrence, drug resistance, and severe side effects. Recent advancements in nano- and precision medicine have introduced tumor-targeted drug delivery strategies through multifunctional nanocarriers which aim to enhance therapeutic efficacy by preventing rapid clearance, prolonging circulation time and improving accumulation at tumor sites while minimizing adverse effects. Although many of these smart Nanotherapeutics are still at the preclinical stage, their unique properties make their promotion in OS clinical applications a challenge. Starting from an overview of the current approved OS therapies, this review reports a systematic analysis of in vivo studies published in the last decade that employ multifunctional nanosystems, drug delivery strategies and cutting-edge technologies in chemo-, immuno- and gene therapy for OS management providing an overview of the potential and challenges of these innovative treatment strategies. Our comprehensive literature analysis points out their certain antitumoral effects in OS preclinical models; however, overcoming translational bottlenecks remains a critical challenge, as promising preclinical findings often fail to translate into effective clinical therapies. Moreover, extended long-term observation in clinical studies is still required together with an in-depth understanding of the unique genetics and biology of OS, given the complex heterogeneity of the tumor microenvironment. By analyzing the limitations of conventional therapies, the latest advancements in nanotechnology alongside key bottlenecks in clinical translation of nanotherapeutics for OS, this review provides valuable insight into future directions, particularly for combination regimens, fostering progress in OS clinical research and supporting the development of innovative and personalized therapies. Introduction Osteosarcoma (OS) represents one of the most frequent malignant bone tumor in adolescents accounting for around 20% of primary malignant bone cancers with high invasiveness, genomic alterations and a strong tendency for pulmonary metastasis. It predominantly affects teenagers, with a smaller secondary peak in individuals over sixty. It primarily arises in the metaphysis of long bones (eg, femur, tibia, humerus) although it can rarely occur at different locations within the axial skeleton.1 Patients with localized tumors have an approximate 5-year survival rate of 70%; however, if metastases are detected or chemotherapy resistance develops, the survival rate drops significantly to 20%.2,3 OS is currently treated by surgery, chemotherapy, and immunotherapy. Historically, amputation was the primary treatment approach. However, scientific advancements and the development of new strategies allowed the adoption of limb-salvage surgery, effective in preserving bone and joint function combining surgery with advanced imaging technique along with “neoadjuvant” and “adjuvant” chemotherapy (before and after surgery, respectively).4,5 As OS is generally a radiation-resistant tumor, radiotherapy is not considered a first-line treatment approach. Instead, it is used after surgery when complete tumor resection is not achievable, to reduce the risk of recurrence or as a definitive treatment for tumors located in anatomically high-risk areas where the tumor is entirely unresectable.6 OS treatment is very complex. The most commonly used first-line chemotherapy regimen in pediatric and young adult patients, known as “MAP”, consists of the combination of high-dose methotrexate (HD-MTX), doxorubicin (DOX) and cisplatin (CDDP), or only DOX and CDDP, as recommended by the National Comprehensive Cancer Network (NCCN) Guidelines for Patients, Bone Cancer 2025.7 However, the use of HD-MTX can be challenging for patients aged > 40 years since they excrete MTX less effectively than adults. Therefore, a combination of DOX, CDDP, and ifosfamide (IFO) can be a suitable alternative (Figure 1A and Table 1). The management of recurrent OS with second-line chemotherapy remains undefined by clear guidelines: treatment strategies are frequently influenced by the duration of the disease-free period and may involve agents such as IFO (high-dose) or cyclophosphamide, either alone or in combination with etoposide or carboplatin, regorafenib and sorafenib (Figure 1B and Table 1). Additional second-line systemic therapy options include gemcitabine (GEM) with or without docetaxel (DTX), sorafenib with everolimus, cabozantinib, cyclophosphamide and topotecan (Figure 1B and Table 1). Moreover, Radium-223 is administered in case of relapsed or refractory OS beyond second-line therapy. Table 1Systemic Therapy Options (First-Line and Second-Line) for OS Patients, Recommended by the NCCN Guidelines Version 1.2025 (https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients)7First-line systemic therapy optionsPreferredoptionsCisplatin and DoxorubicinHigh-dose Methotrexate, Cisplatin and Doxorubicin (MAP)Other recommendedDoxorubicin, Cisplatin, Ifosfamide and high-dose MethotrexateSecond-line systemic therapy optionsPreferred optionsIfosfamide (high dose) with or without etoposideRegorafenibSorafenibOther recommendedCabozantinibCyclophosphamide and TopotecanGemcitabine with or without DocetaxelSorafenib with EverolimusUsed in some casesCyclophosphamide and EtoposideIfosfamide, Carboplatin and EtoposideHigh-dose MethotrexateHigh-dose Methotrexate, Etoposide and IfosfamideRadium-223 for relapsed or refractory disease beyond second-line therapy Figure 1Chemical structure of first-line (A) and second-line (B) chemotherapies recommended for OS patients by the NCCN Guidelines7 Version 1.2025. Table 1Systemic Therapy Options (First-Line and Second-Line) for OS Patients, Recommended by the NCCN Guidelines Version 1.2025 (https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients)7First-line systemic therapy optionsPreferredoptionsCisplatin and DoxorubicinHigh-dose Methotrexate, Cisplatin and Doxorubicin (MAP)Other recommendedDoxorubicin, Cisplatin, Ifosfamide and high-dose MethotrexateSecond-line systemic therapy optionsPreferred optionsIfosfamide (high dose) with or without etoposideRegorafenibSorafenibOther recommendedCabozantinibCyclophosphamide and TopotecanGemcitabine with or without DocetaxelSorafenib with EverolimusUsed in some casesCyclophosphamide and EtoposideIfosfamide, Carboplatin and EtoposideHigh-dose MethotrexateHigh-dose Methotrexate, Etoposide and IfosfamideRadium-223 for relapsed or refractory disease beyond second-line therapy Systemic Therapy Options (First-Line and Second-Line) for OS Patients, Recommended by the NCCN Guidelines Version 1.2025 (https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients)7 Cisplatin and Doxorubicin Cisplatin and Doxorubicin High-dose Methotrexate, Cisplatin and Doxorubicin (MAP) High-dose Methotrexate, Cisplatin and Doxorubicin (MAP) Doxorubicin, Cisplatin, Ifosfamide and high-dose Methotrexate Doxorubicin, Cisplatin, Ifosfamide and high-dose Methotrexate Ifosfamide (high dose) with or without etoposide Ifosfamide (high dose) with or without etoposide Regorafenib Regorafenib Sorafenib Sorafenib Cabozantinib Cabozantinib Cyclophosphamide and Topotecan Cyclophosphamide and Topotecan Gemcitabine with or without Docetaxel Gemcitabine with or without Docetaxel Sorafenib with Everolimus Sorafenib with Everolimus Cyclophosphamide and Etoposide Cyclophosphamide and Etoposide Ifosfamide, Carboplatin and Etoposide Ifosfamide, Carboplatin and Etoposide High-dose Methotrexate High-dose Methotrexate High-dose Methotrexate, Etoposide and Ifosfamide High-dose Methotrexate, Etoposide and Ifosfamide Radium-223 for relapsed or refractory disease beyond second-line therapy Radium-223 for relapsed or refractory disease beyond second-line therapy Chemical structure of first-line (A) and second-line (B) chemotherapies recommended for OS patients by the NCCN Guidelines7 Version 1.2025. OS exhibits a complex and highly heterogeneous tumor microenvironment (TME) and the pathologic mechanisms driving tumor progression and metastasis remains poorly understood.8 Mesenchymal stem cells (MSCs) along with osteoblast and osteoclast are key players in the development and progression of OS (Figure 2). Although the etiology is not well understood, many biomarkers have been identified: the most frequently mutated genes in OS are TP53, Rb, CDK, c-Myk and TGF-β.9 These mutations play a critical role in tumorigenesis by disrupting key cellular processes such as cell cycle regulation, apoptosis, and differentiation, thereby contributing to the aggressive and metastatic nature. Pre-existing conditions represent another significant risk factor for OS development. Some rare inherited disorders are currently recognized as being associated with OS, including Li-Fraumeni syndrome (caused by TP53 mutations), Retinoblastoma (characterized by mutations to Rb1), and Werner syndromes (WRN gene mutation). These conditions frequently associated with mutations in key tumor suppressor genes, such as TP53 and Rb1, contribute to genomic instability and raise the risk of developing OS and other malignancies.10 The rapid growth of tumoral cells interferes with normal bone remodeling, resulting in osteolytic damage and aggressive lesions that weaken the bone structure, invade adjacent soft tissues, and lead to localized compression and swelling. Figure 2Some of the cellular pathways involved in OS development: initially, osteosarcomagenesis was considered to originate only from mesenchymal stem cells, whereas currently it’s well known that OS can develop from osteoblasts, dysregulated osteoclasts in addition to mesenchymal stem cells. Some of the cellular pathways involved in OS development: initially, osteosarcomagenesis was considered to originate only from mesenchymal stem cells, whereas currently it’s well known that OS can develop from osteoblasts, dysregulated osteoclasts in addition to mesenchymal stem cells. The progress of OS is also influenced by epigenetic factors, such as methylation, histone modification and non-coding RNA that regulate genes expression. Their dysregulation may interfere with essential signaling pathways governing cell proliferation, apoptosis, and metastasis, thereby enhancing the aggressiveness of OS.11 Studies of the OS TME consistently reveal immune cell infiltration,12 paving the way for immunotherapies such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T cells and bispecific antibodies which are currently under clinical investigation. Moreover, approaches involving modified NK cells/macrophages, vaccines, and cytokines hold promise to be hot topics for future.13 The aim of these strategies is to boost the natural immune response to recognize and destroy cancer cells, offering encouraging prospects for treating OS, especially in immuno-combination strategies. Furthermore, considering that genetic mutations are among the most fundamental causes of OS, gene therapy could offer a promising approach by inserting therapeutic genes into target cells to correct genetic mutations and/or provide therapeutic effects. However, despite notable advancements and valuable prospects, OS gene therapy still remains in the experimental stage requiring further research for its clinical translation.3 Although treatment strategies have been extensively refined over time, the management of OS remains challenging due to persistent issues that strongly complicate therapeutic approaches including drug resistance, recurrence, metastasis, immune suppression, systemic toxicity, and poor blood flow and vascularization within bone tissue. However, these challenges serve as an impetus for the exploration of new treatment tactics. In this framework, drug delivery nanoplatforms could offer promising solutions for OS fighting by enhancing drug penetration and accumulation in tumor tissues (enhanced permeability and retention, EPR effect), prolonging circulation time, and increasing drug solubility. Several literature reviews recently summarized the promises and challenges of drug delivery systems for OS treatment focusing on suitable biomaterials, active targeting ligands and stimuli-responsive strategies.14–18 Nano-sized drug delivery systems tested in vivo against OS in the last decade mainly include liposomes, hydrogels, polymeric nanoparticles and micelles, inorganic nanoparticles and exosomes. Although these nanocarriers offer controlled and sustained drug release and can passively accumulate in tumor tissues (due to the leaky vasculature and impaired lymphatic drainage), they are limited by non-specific targeting and low drug diffusion within the tumor. To address these challenges, active targeting strategies have been widely explored by decorating nanocarriers with specific ligands able to achieve bone tissue targeting and/or OS cell targeting.14 For instance, small-molecules such as bisphosphonates (eg, alendronate and zoledronate), phytic acid, aspartic acid-rich peptides, and tetracyclines exhibit high affinity for hydroxyapatite (HAp, Ca10(PO4)6(OH)2) that represents an ideal target for bone since constitutes its primary mineral component. The binding of these anion-rich ligands to HAp is mediated by chelation of surface-exposed calcium ions.14 Moreover, integrin-targeted approaches, especially those involving RGD peptides, have demonstrated notable potential in both in vitro studies19 and in preclinical OS models.20 Also, CXCR1 peptide, hyaluronic acid and folic acid have been fruitfully selected for the development of OS targeted drug delivery nanosystems.14 This comprehensive review aims to provide valuable insights into the most recent nanotechnological advancement in OS management pointing out the promising potential of nanomedicine-boosted therapy. The review reports a systematic and comprehensive analysis of in vivo studies published in the last decade that employ multifunctional Nanotherapeutics, drug delivery strategies and cutting-edge technologies in chemotherapy, immunotherapy and gene therapy against OS, discussing the limitations of conventional treatment approaches, the remaining challenges and the future trend. Overall, this review aims (1) to provide a reference for current approved OS treatment, (2) to summarize the advantages and disadvantages of existing chemotherapeutics, (3) to discuss translational bottlenecks and future perspectives, especially for combination regimens, (4) to promote progress in OS clinical research and to contribute to future innovation in personalized treatments. Challenges of OS Chemotherapy: Might Nanotechnology Break the Current Treatment Limit? Standard OS treatment involves a sequential approach combining chemotherapy with surgical resection. Chemotherapy was originally used as an “adjuvant” treatment following surgical resection to eradicate residual tumor cells and metastases. Subsequently, “neoadjuvant” chemotherapy was introduced prior to surgery based on the assumption that it can reduce the inflammatory response at the tumor’s margins, inhibit new blood vessel formation, shrink the tumor, making surgical removal easier, and provide time for surgical planning. Although there is a lack of evidence showing that it leads to better clinical outcomes, the combination of surgical resection with multi-drug chemotherapy is currently the standard procedure to treat OS.21,22 Despite various combinations of chemotherapeutics being developed to enhance therapeutic efficacy, significant advancements in treatment outcomes have been affected by drug resistance and metastasis. Drug resistance in OS is mainly associated with mechanisms such as overexpression of the membrane drug transporters (eg, ATP-binding cassette known as “ABC transporters”), enhanced DNA repair, alterations in apoptosis-related genes, and the involvement of noncoding RNAs.23 Another crucial element involved in chemotherapy resistance is the OS TME, a highly complex and heterogenous biological community consisting of immune cells such as T cells, macrophages and dendritic cells, cytokines and immunomodulators that collectively influence the response to cancer treatment.12 Furthermore, drug resistance in OS is intricately linked to its metastatic potential, as the mechanisms that confer resistance often enhance the aggressiveness of the disease. Overexpression of ABC transporters, for instance, not only reduces the intracellular accumulation of chemotherapeutic agents but also promotes survival pathways that facilitate metastatic spread. Similarly, enhanced DNA repair mechanisms and alterations in apoptosis-related genes allow tumor cells to survive cytotoxic stress, providing a survival advantage during dissemination. Moreover, noncoding RNAs play a dual role, contributing to both chemoresistance and regulation of genes associated with invasion and metastasis.24 Even though significant efforts are currently being made to tackle this disease, the 5-year survival rate for patients with metastatic OS remains unsatisfactory.25 Addressing these complex interconnected pathways requires innovative approaches: in this context, the use of nanotechnology in drug delivery might enable personalized medicine, tailoring therapies to specific patient’s needs. Nanotherapeutics holds the promise for overcoming traditional barriers and limitations and improving therapeutic outcomes in resistant and metastatic OS. DOX-Nanotherapeutics Doxorubicin (DOX) is a widely used chemotherapeutic agent able to disrupt multiple cellular processes in cancer cells.26 Its primary mechanism involves the intercalation into DNA where it inserts between base pairs, impairing critical functions such as replication and growth. Furthermore, DOX inhibits topoisomerase II, an enzyme essential for DNA transcription and replication. By inhibiting the DNA-topoisomerase II complex, it induces double-strand breaks, resulting in genomic instability and triggering apoptosis. This action is complemented by the drug’s disruption of mitochondrial function, leading to increased generation of reactive oxygen species (ROS) and oxidative damage to lipids, proteins, and nucleic acids. DOX cytotoxic effects promote apoptosis, autophagy, and ferroptosis, depending on the cellular environment. However, DOX’s effectiveness is restricted by the development of resistance and the occurrence of side effects. These include overexpression of ABC transporters, which actively expel the drug from cells, as well as enhanced DNA repair mechanisms and mutations in apoptosis-regulating genes (ie, TP53). The TME itself, often characterized by hypoxia and protective stromal components, further decreases DOX efficacy.27 Common short-term DOX chemotherapy side effects (eg, nausea, vomiting, diarrhea, and bone marrow suppression) are generally acute and reversible. However, anthracycline treatment also involves the risk of long-term complications, including cardiotoxicity, therapy-related malignancies, and gonadotoxicity.28 Efforts to mitigate these adverse effects have focused on developing advanced drug delivery systems that can selectively target tumor tissues. Various DOX nanoformulations, including liposomes, polymeric nanoparticles and micelles, dendrimers, and exosomes have demonstrated improved therapeutic performance by improving drug accumulation within tumor tissue and minimizing systemic toxicity, as well reviewed by D’Angelo et al.29 In the development of liposomal DOX,30–32 OLV-DOX (oligolamellar liposome) was the first formulation to progress into clinical trials; however, it did not achieve the expected results mainly due to the fast clearance by the reticuloendothelial system, the large particle size and the drug leakage before reaching the target site. Technological advancements in DOX nanomedicine have led to the successful development of Doxil®/Caelyx® (US/EU, respectively), the first PEGylated liposomal formulation of DOX composed of hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPE-mPEG2000) in a 3:1:1 weight-to-weight ratio, respectively.33 Doxil, known for its low cardiotoxicity and improved pharmacokinetic profile, was approved in 1995 by FDA and in 1996 by EMA. It is commonly used to treat recurrent ovarian cancer, metastatic breast cancer, AIDS-related Kaposi’s sarcoma and multiple myeloma. However, it is not indicated for OS treatment and only limited and outdated scientific literature is currently available to evaluate its efficacy in this context.34–37 The transition from OLV-DOX to Doxil® strongly emphasized the importance of: a) downsizing the particle size to exploit the enhanced retention and permeation (EPR); b) surface modification for active targeting and tissue specific drug delivery, to minimize toxicity and achieve maximum therapeutic benefit; c) promoting stable and suitable entrapment of drug until it reached the target site, being crucial to reduce drug leakage. In the last decade, different liposomal DOX formulations were developed to improve selectivity and efficacy, exploiting the advantages of chemical functionalization, stimuli-responsiveness (ie, temperature, light, pH) and co-delivery with other drugs. In this context, in a Phase I clinical trial (Trial registration number: ChiCTR1900021550) in patients with metastatic and recurrent OS, a combination of PEGylated liposomes encapsulating DOX (Duomeisu®, 50 mg/m2) and CDDP (100 mg/m2) demonstrated good tolerability with a favorable safety profile (reduced cardiotoxicity)38 and encouraging clinical activity in advanced OS warranting further investigation in Phase II studies, not yet carried out. A separate phase II clinical trial is currently investigating the combination of Duomeisu® with cyclophosphamide and vincristine for recurrent or refractory solid tumors, including OS. An interesting OS-targeted liposome was developed by Feng et al incorporating alendronate (ALN) as a bone-targeting moiety and hyaluronic acid (HA) as a ligand for CD44 receptors which are frequently overexpressed in OS cells.39 ALN-HA conjugate was linked to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]-carboxylate (DSPE-PEG2000-COOH) via disulfide bond to impart redox sensitivity. The functionalized lipid ALN−HA−SS−L was then incorporated into preformed DOX-loaded liposomes resulting in the ALN−HA−SS−L−L/DOX final formulation. Preclinical trial of this formulation in MG-63 tumor-bearing mice showed higher antitumoral activity compared to HA-L-L/DOX and PEG-L/DOX. The co-administration of tumor-penetrating peptide RGD enhanced the uptake of liposomes and consequently their efficacy, providing additional benefits. Innovative hyaluronated liposomes containing H2S-releasing DOX (HA-Lsdox) were proposed by Gazzano et al to mitigate the severe cardiotoxicity and multidrug resistance commonly associated with conventional DOX.40 It’s well known that the overexpression of the efflux pump P-glycoprotein (Pgp) (also known as ATP binding cassette B1/P-glycoprotein, ABCB1/Pgp) is a negative prognostic factor in OS patients. In fact, this overexpression leads to multidrug resistance and reduces the effectiveness of chemotherapy, including DOX treatment, ultimately impacting patient survival. Sdox was designed as a novel hydrogen sulfide (H₂S)-donating derivative of DOX with improved profile respect to the native drug, able to exert cardioprotective effects, to reduce oxidative stress, and to enhance drug sensitivity in resistant cancer cells. sDox was loaded in hyaluronated liposomes able to target CD44 receptors allowing for enhanced specificity and uptake in the TME. In vivo experiments using xenograft models (Balb/C mice) expressing Pgp (DOX-resistant) and HA receptor CD44 confirmed that HA-Lsdox enhanced drug accumulation in tumor tissues compared to DOX, Caelyx, Sdox, and Lsdox, maintaining reduced cardiotoxicity. A promising advancement concerned the development of liposomal DOX decorated with low-density lipoprotein (LDL) as a novel therapeutic approach for drug resistant OS.41 Since the resistance to DOX is mainly due to an increased drug efflux (due to overexpression of ABC transporter Pgp) and a decreased drug uptake, Gazzano et al proposed a pioneering two-phase treatment involving the sequential administration of atorvastatin (as a pure chemosensitizing agent) and LDL-masked liposomal DOX. Specifically, atorvastatin was able to increase the levels of surface LDL receptors (LDLR) by decreasing cholesterol biosynthesis, thereby promoting the uptake of DOX loaded into the liposomal formulation properly decorated with an LDLR-binding peptide. The sequential administration of atorvastatin followed 24 h later by LDL-decorated liposomal DOX demonstrated strong efficacy also in vivo, significantly reducing tumor growth in a preclinical model of resistant OS established by subcutaneous implantation of U-2OS/DX580 cells in adult nu/nu Balb/c mice. Stimuli-responsive hydrogels represent an innovative approach for localized and targeted DOX delivery against OS.42 A chitosan-based thermosensitive injectable hydrogel incorporating black phosphorus (BP) nanosheets as photothermal agents (BP/DOX/CS) was designed by Li et al to release DOX in a controlled and sustained way under light irradiation.43 When exposed to near-infrared (NIR) light, the hydrogels underwent a sol-gel transition that induced controlled DOX release. The BP nanosheets converted light into heat with high efficiency inducing localized hyperthermia that killed tumor cells. At the same time, they released phosphates which stimulate osteogenic differentiation and contributed to bone tissue regeneration. The thermosensitive BP/DOX/CS hydrogel, ensuring good drug loading capacity and prolonged delivery of DOX, combined both photothermal therapy and chemotherapy enhancing therapeutic efficacy in K7M2-WT OS cells. Furthermore, injection of BP/DOX/CS hydrogel at the tumor site in BALB/c female mice efficiently eradicated the tumor without systemic toxic effects. Zhang et al recently developed a versatile hydrogel composed of amino-polyethylene glycol folic acid (NH2-PEG-FA) and black phosphorus nanosheets (BPNSs) for the targeted delivery of DOX (Figure 3).44 The BPNSs, synthesized using the liquid-phase stripping method, possessed a negatively charged surface that electrostatically interacted with the positively charged NH2-PEG-FA, resulting in BPNSs-PEG-FA/DOX after DOX encapsulation. Finally, the thermosensitive BPNSs-PEG-FA/DOX@Hydrogel was prepared via a cold method. Upon exposure to 808 nm NIR light which penetrated biological tissues effectively, the BPNSs at the OS lesion site were activated to generate localized heat. This process induced K7M2-WT OS cell apoptosis and hydrogel erosion improving DOX release. Importantly, toxicity studies on BALB/c mice locally injected with the hydrogel confirmed their biocompatibility and safety since both the BPNSs and the hydrogel were safely excreted via the kidneys. This innovative system integrated NIR light-induced controlled drug release, active tumor targeting via folic acid receptors, and photothermal therapy, establishing a robust and multifunctional strategy for OS treatment. Furthermore, degradation products of BPNSs contributed to bone regeneration through bio-mineralization, offering dual therapeutic benefits. Figure 3Schematic illustration of the chemical components and the preparation of multifunctional BPNSs-PEG-FA/Dox@Hydrogel for chemotherapy and photothermal therapy against OS.44Notes: Reprinted from Zhang Z, Yang JY, Chen JH, et al. Construction and evaluation of a folate-mediated Adriamycin phosphorene thermosensitive hydrogel delivery system against osteosarcoma. Appl Mater Today. 2024;40:102386 Copyright 2024, with permission from Elsevier.44 Schematic illustration of the chemical components and the preparation of multifunctional BPNSs-PEG-FA/Dox@Hydrogel for chemotherapy and photothermal therapy against OS.44 A different approach to modulate drug release and minimize the toxicity of DOX involves the use of pH-responsive hydrogels based on surfactant-like peptides (SLPs). A recent study45 demonstrated that a nonapeptide, synthesized via solid-phase synthesis, can form a stable hydrogel at neutral or alkaline conditions (pH 7.4/9.2), while transitioning to a fluid state under mildly acidic conditions (pH 5.8). This pH-sensitive behavior was validated by in vitro and in vivo studies (K12 orthotopically grown in BALB/c mice) which demonstrated effective DOX release within the acidic microenvironment characteristic of OS tumor cells. A methacrylic gelatin/oxidized dextran/montmorillonite-strontium/polypyrrole (GOMP) was recently proposed by Liu et al.46 This research explores the use of gelatin methacrylamide (GelMA) as a hydrogel matrix for chemotherapy and photothermal treatment of OS. The hydrogel was prepared through UV-triggered polymerization combined with Schiff base formation between GelMA and oxidized dextran (Odex). To enhance its functionality, the interlayer space of montmorillonite (MMT) was utilized to incorporate Sr2+ ions, creating Sr ion-doped MMT (MMT-Sr) which was integrated into the GelMA/Odex hydrogel. MMT-Sr not only enhanced the hydrogel’s mechanical strength but also supported and promoted bone regeneration. Additionally, the hydrogel was loaded with DOX and polypyrrole-polyvinylpyrrolidone (PPy-PVP) nanoparticles for NIR-photothermal responsiveness. The synergistic chemo- and photothermal effects of multifunctional DOX-loaded GOMP hydrogel were confirmed both in vitro in human 143B OS cells and in vivo in tumor-bearing Balb/c mice. An innovative and synergistic approach combining chemodynamic and photothermal therapy against OS relies in an injectable agarose hydrogel designed to encapsulate DOX-loaded iron-gallic acid nanoparticles (Fe-GA NPs) and tested in vitro in K7M2wt OS cells and in vivo in K7M2wt subcutaneous tumour-bearing mice.47 The Fe-GA NPs served as the core of the system, leveraging the ions’ ability to catalyze hydrogen peroxide into hydroxyl radicals (•OH) through Fenton-like reactions, inducing oxidative stress in tumor cells. This chemodynamic effect was further enhanced by localized photothermal therapy achieved through the photothermal conversion capability of Fe-GA NPs under NIR light. Exosomes are small extracellular vesicles (30–150 nm) that play a key role in intercellular cross-talk by transferring molecular cargo between cells being crucial in various physiological and pathological processes, such as immune regulation, cancer growth and progression, and therapeutic responses. They are typical cancer biomarkers of liquid biopsy.48 The significance of exosomes in OS research was well demonstrated in the systematic review and meta-analysis of Liu et al, which comprehensively analyzed the advancement of preclinical research related to exosome and OS, aiming to support future investigations.49 Increasing evidence shows that exosomes regulate OS progression and development, playing a crucial role in tumorigenesis, proliferation, metastasis, angiogenesis, immune evasion and chemoresistance, as well reviewed by Yang and coworkers.50 Furthermore, exosomes are currently investigated not only as biomarkers or therapeutic targets but also as drug delivery vehicles for OS therapy. In this framework, exosomes (Exo) derived from bone marrow mesenchymal stem cells (BM-MSCs) were proposed by Wei et al for DOX delivery (Exo-DOX), owing to their tumor-targeting migration properties.51 Exo-DOX demonstrated increased cellular uptake and tumor suppression in MG63, HOS, and 143B cell lines and low cardiotoxicity compared with free DOX. The in vivo results confirmed that Exo-DOX effectively delivered DOX at OS sites and mitigated tumor progression. Specifically, a 6-fold reduction of tumor volume was observed at day 21 following Exo-DOX administration compared with free DOX group. Interestingly, the targeting ability of Exo-DOX could be attributed to the chemotaxis of MSC-derived exosomes to OS due to the specific interaction of OS CXCR4 membrane proteins with SDF-1 protein expressed by BM-MSCs. One significant challenge limiting the broader use of exosomes is the high cost, time-consuming isolation, and the need for skilled technicians associated with current separation technologies. To address these obstacles, hybrid exosomes (HE) have been produced on a large scale by membrane fusion technology by hybridizing exosomes with synthetic liposomes.51 This innovative approach not only satisfies the growing demand for exosomes but also further reduces immunogenicity of liposomes. In a recent study, exosomes secreted by BM-MSCs were fused with liposome membranes and loaded with DOX.52 The HE/DOX were tested in vitro against 143B and MG63 OS cell lines, as well as in an orthotopic model created by injecting 143B cells into the tibia of nude mice. An enhanced efficacy was obtained compared to both free DOX and liposomes loaded with DOX, along with pH-sensitive DOX release. The drug release from HE/DOX at pH 5.5 reached up to 82%, whereas it was only 58% under physiological pH, likely due to the disruption of the vesicle structure in acidic conditions, together with DOX protonation which accelerates drug release. Another approach to overcome some of the practical limitations of exosome-based drug delivery, such as low yield, complex isolation procedures, and batch variability is the use of exosomes mimetics (EM), artificially engineered vesicles designed to replicate the biological functions and structural characteristics of natural exosomes.53 Recently, Wang et al proposed a EM/DOX system to treat OS prepared by sequential extrusion of BM-MSCs followed by incorporation of DOX exploiting the active-loading approach (ie, ammonium sulfate gradient method).54 The size of EM-DOX became larger following DOX loading but still fell within 30–200 nm range which assured good biodistribution and permeability. The release profile pointed out that also EM/DOX was sensitive to the acidic environment likely due to DOX protonation that accelerated drug release (about 80% at pH 5.5 vs 60% at pH 7.4 within 48 h). The in vitro studies in 143B and MG63 OS cells and the in vivo assay in tumor-bearing BALB/c nude mice demonstrated excellent antitumoral properties and fewer side effects compared to free DOX. Despite their promising potential in diagnostics, drug delivery, and regenerative medicine, no exosomes-products have been approved by FDA for therapeutic use so far. Current challenges for clinical translation of exosomes primarily fall into three key areas: production (large-scale manufacturing, heterogeneity minimization, batch-to-batch consistency, storage stability, cost control), clinical application (knowledge of exosome dosage, biodistribution, uptake, half-life), and regulation hurdles (lack of standardized industrial protocols for manufacturing, shipping and quality control, stability, safety, and potency). CDDP-Nanotherapeutics Cisplatin (CDDP, cis-diamminedichloroplatinum(II)) is a chemotherapeutic drug that exerts its effects by targeting DNA of cancer cells. Upon entering the cell after passive diffusion and active transport, CDDP becomes activated (Figure 4) due to the displacement of one or both chloride ligands by water molecules (mono-aqua and di-aqua species are formed).55,56 This complex reacts preferentially with nitrogen atoms of purine bases in DNA and sulfhydryl groups of proteins. The consequent formation of intrastrand and interstrand cross-links within DNA triggers various cellular stress responses, including the activation of repair mechanisms. If the damage is extensive and irreparable, it leads to the activation of apoptotic pathways causing programmed cell death. In addition, CDDP increases the concentration of ROS by interfering with the cellular antioxidant defense systems. ROS accumulation, combined with the direct damage caused by CDDP to mitochondria, disrupts mitochondrial function and triggers the activation of apoptotic pathways. Figure 4Mechanism of action of CDDP at the cellular level. Mechanism of action of CDDP at the cellular level. CDDP is generally used for treating testicular, ovarian, bladder, lung cancer and OS but its primary drawbacks are the toxicity and the propensity to induce resistance.57,58 Mechanisms of resistance to CDDP can be categorized into several types (ie, pre-target, on-target, post-target, off-target).59 Pre-target resistance refers to alterations in the processes controlling cisplatin’s transport into and out of the cell. Two key transporter families have been identified as pivotal in cisplatin transport: organic cation transporters (OCTs) and organic anion transporters (OATs) play a significant role in drug influx, facilitating the entry of CDDP into cells. On the other hand, ABCC2, a member of the ABC transporter family, appears to be critically involved in the efflux of cisplatin, contributing to drug resistance by reducing intracellular drug accumulation. On-target resistance refers to alterations in cellular mechanisms that address DNA damage induced by CDDP. For instance, nucleotide excision repair (NER) plays a crucial role by removing platinum-DNA adducts. This process relies on the action of proteins such as ERCC1 (Excision Repair Cross-Complementation Group 1) and XPF (Xeroderma Pigmentosum Complementation Group F). Notably, these proteins are often overexpressed in cisplatin-resistant patients, enhancing the cell’s ability to repair DNA lesions and thereby reducing the drug’s efficacy. Post-target resistance involves mechanisms that interfere with the pathways responsible for initiating cell death following the formation of cisplatin-induced DNA adducts. Notably, this includes the inactivation of the TP53 gene, a critical tumor suppressor, and the upregulation of caspase inhibitory proteins which block apoptosis. Off-target resistance, on the other hand, disrupts cisplatin-induced pro-apoptotic signaling. Key contributors include overexpression of genes such as HER2 (human epidermal growth factor receptor 2) and DYRK1B (dual specificity tyrosine phosphorylation-regulated kinase 1B). These proteins not only promote tumor growth but also enhance the tumor’s ability to withstand oxidative stress, further undermining cisplatin’s therapeutic effectiveness. Another significant issue associated with CDDP treatment is its toxicity, which has the potential to impact all organs. However, the kidneys are particularly vulnerable, often resulting in oliguria, since CDDP is primarily excreted through the urine, leading to renal concentrations that can be up to five times higher than those observed in the serum. To elude clinical CDDP resistance and reduce side effects, several platinum analogues with higher physiological stability have been developed (eg, carboplatin and oxaliplatin) and FDA-approved, referred to as the “second generation of Pt chemotherapeutics”.60 Moreover, various nanocarriers have been explored for improving the therapeutic potential of CDDP and overcoming the major drawbacks and limitations including chemoresistance, toxicity, and low water solubility (ie, 1 mg/mL). Among them, liposomes, hydrogels and nanoparticles gained significant attention. Gu et al proposed a hyaluronidase-responsive multi-layer liposome (HLCN) to increase the potency of liposomal CDDP. The HLCN system was designed for the co-delivery of cisplatin and siRNA targeting the transcription factor Nrf2 (siNrf2), aiming to suppress Nrf2 expression and subsequently increase ROS levels within tumor cells.61 The liposome core composed of phosphatidylcholine and cholesterol (10:1 mass ratio) was coated with a layer of Vpr52-96 peptide which encapsulated siNrf2 and an outer layer of polyethyleneimine-hyaluronic acid (PEI-HA) serving as a ligand for CD44 receptors. Once internalized, the HA layer can be cleaved by endosomal hyaluronidase, exposing the underlying PEI layer which facilitates endosomal escape. Additionally, Vpr52-96 was reported to induce apoptosis by promoting mitochondrial permeabilization, further enhancing the therapeutic potential of the system. Overall, the cytotoxicity of HLCN (IC50 1 μM) resulted four times lower than liposomal CDDP (IC50 4 μM). Notably, HLCN markedly inhibits tumor growth in xenograft OS mice with minimal systemic toxicity. pH-sensitive HA-based nanocarriers were developed for the combined delivery of CDDP, DOX and resiquimod (R848), an agonist of Toll-Like Receptor 7/8 (TLR7/8) used as immunotherapy agent.62 The nanoparticles were produced by nanoprecipitation in the presence of poly-L-histidine for pH responsiveness. Upon intravenous administration, the drug-loaded nanoparticles released their cargo in the acidic TME. Antitumor efficacy was tested in vivo using a K7M2 orthotopic OS mouse model, demonstrating satisfactory tumor suppression as well as stimulation of the immune response. The synergistic combination of DOX and CDDP induced immunogenic cell death (ICD) of tumor cells, a special autophagy pathway that triggered tumor-associated antigen (TAA) release and antigen-specific immune response while the delivery of resiquimod consistently activated the immune system to enhance antigen presentation in the tumor. A novel approach to reduce toxicity and enhance the effectiveness of CDDP was achieved by incorporating 3D-printed porous Ti6Al4V implants loaded with cisplatin into a PLGA-PEG-PLGA hydrogel.63 Compared to traditional titanium alloy implants, 3D-printed porous Ti6Al4V implants (Figure 5) displayed a significantly lower elastic modulus and stiffness, mimicking more closely the mechanical properties of cortical bone. PLGA-PEG-PLGA hydrogels, on the other hand, are ideal for drug delivery due to their non-toxic and biodegradable nature, high drug loading capacity, and thermoresponsive gelation behavior when exposed to heat. This strategy was tested both in vitro and in vivo demonstrating safety and effectiveness. Specifically, the implants demonstrated a better effect and reduced adverse effects compared to conventional systemic CDDP delivery in a tumour-bearing female BALB/c nude mouse model, inducing higher tumor cell apoptosis, lower body weight loss, and poor organ toxicity. Moreover, the bone repair effect of the implants was evaluated in bone defect rabbit models. Notably, since both Ti6Al4V implants and PLGA-PEG-PLGA hydrogels have already been approved for clinical use, this approach holds significant potential for clinical translation. Figure 5Schematic illustration of the preparation of cisplatin/hydrogel-loaded 3D-printed Ti6Al4V implants with anti-tumour and bone-repair effects.63Notes: Reproduced with permission from Jing Z, Ni R, Wang J et al. Practical strategy to construct anti-osteosarcoma bone substitutes by loading cisplatin into 3D-printed titanium alloy implants using a thermosensitive hydrogel. Bioact Mater. 2021;6(12):4542–4557. doi.org/10.1016/j.bioactmat.2021.05.007 © 2021 The Authors. Published by Elsevier Ltd. under the CC BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by-nc-nd/4.0/).63 Schematic illustration of the preparation of cisplatin/hydrogel-loaded 3D-printed Ti6Al4V implants with anti-tumour and bone-repair effects.63 The same PLGA-PEG-PLGA triblock copolymer hydrogel was also evaluated as an injectable formulation for sustained and localized co-delivery of DOX and CDDP.64 The synergistic efficacy of multi-drugs co-loaded hydrogels was confirmed both in vitro in Saos-2 and MG-63 cells and in vivo in a human OS nude mice xenografts model. Moreover, ex vivo histological analysis suggested low systemic toxicity by localized injection. A photopolymerizable hydrogel based on glycol chitosan (GC) integrated with (2-hydroxypropyl)-β-cyclodextrin (HP) was proposed for the co-delivery of DOX and CDDP.65 In vitro and in vivo anticancer effects were evaluated in Human Bone OS cell line (KHOS-NP) and in OS cancer-bearing xenograft mouse model, respectively. The GC-HP@DOX@CDDP nanosized hydrogel was locally injected once a week for four consecutive weeks enabling a controlled and sustained drug release and improving in vivo localized efficacy without cardio- or nephrotoxicity. Recent advancements in cancer therapy and the understanding of a close relationship between tumor progression, therapeutic resistance and TME led to the development of innovative drug delivery systems which offer enhanced therapeutic potential by targeting TME elements or their signaling pathways.12 A recent study highlighted the development of a TME-based prognostic index for OS which helps predict patient outcomes based on TME characteristics.66 The work revealed correlations between a high TME index and the expression of specific factors including the oncogene MYC, which is one of the most frequently activated oncogenic proteins in human tumors (nearly one-fourth of OS shows MYC amplification and the worst clinical outcomes). In this framework, a TME-responsive nanocomposite hydrogel that delivered a MYC inhibitor (NHWD-870) and Interleukin 11 receptor alpha (IL11Rα)-targeted liposomes containing cisplatin-loaded mesoporous MnO2 was developed to improve OS treatment outcomes by reshaping the TME and enhancing immune responses.67 The injectable hydrogel was composed of poly(3-amino-4-methoxybenzoic acid)-gelatin-thioketal (PAMB-G-TK) which created a polymer responsive to ROS by reacting with the succinimide functionalities of 4-arm-PEG-SG. Liposomes encapsulated in the hydrogel were directed towards tumor cells via surface modification with IL11. Moreover, MnO2 and cisplatin were integrated into IL11Rα-targeted liposomes (Figure 6). Upon intratumoral injection, the hydrogel degraded and released the therapeutic molecules. MYC inhibition therapy can suppress the production of downstream cytokines such as CCL2 and IL13, thereby encouraging the reprogramming of tumor-promoting M2 macrophages into anti-tumor M1 macrophages. In the TME, GSH facilitates the reduction of MnO2 to Mn2+ triggering a Fenton-like reaction producing ROS for chemodynamic therapy. Notably, the released cisplatin and Mn2+ induce ICD which enhances the maturation of dendritic cells (DCs). These mature DCs, along with M1 macrophages, stimulated T cells increasing immune infiltration and effectively inhibiting tumor proliferation and metastasis. The limitation of this study, by the authors’ own admission, lies in the evaluation of effectiveness in mouse-derived models rather than patient-derived xenografts (PDX). Figure 6Schematic illustration of the preparation and biological effect of the injectable TME-responsive nanocomposite hydrogel loaded with an effective MYC inhibitor (NHWD-870) and IL11Rα-targeted liposomes containing cisplatin-loaded MnO2 (Cis/Mn@Lipo-IL11).67Notes: Reproduced with permission from Ma Y, Lai P, Sha Z et al. TME-responsive nanocomposite hydrogel with targeted capacity for enhanced synergistic chemoimmunotherapy of MYC-amplified osteosarcoma. Bioact Mater. 2025;47:83–99. https://doi.org/10.1016/j.bioactmat.2025.01.006. © 2025 The Authors. Published by Elsevier Ltd. under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).67 Schematic illustration of the preparation and biological effect of the injectable TME-responsive nanocomposite hydrogel loaded with an effective MYC inhibitor (NHWD-870) and IL11Rα-targeted liposomes containing cisplatin-loaded MnO2 (Cis/Mn@Lipo-IL11).67 Recently, Sun et al developed an amphiphilic Platinum (IV) prodrug (ALN-PtIV-Lipo) for OS targeting chemotherapy and bone destruction inhibition.68 The prodrug consisted of three covalently bound moieties: hydrophilic alendronate (ALN, targeting group), CDDP (DNA cross-linking agent), and a long hydrophobic lipid tail (Figure 7). The self-assembly of ALN-PtIV-Lipo produced PtIV lipid nanoparticles (APtIV, 31 nm) with an IC50 in K7M2 cells of 1.42 μM, which is only one eighth of that of CDDP. APtIV nanoparticles intravenously injected in an OS mouse model rapidly targeted the tumor site exploiting the in vivo coordination between phosphonate and Ca2+ that improved Pt endocytosis by OS cells that typically owned higher Ca2+ levels respect to other types of cancer tissues, due to an increased Ca2+ metabolism. The prodrug nanoparticles effectively inhibited tumor growth (tumor growth inhibition, TGI 86% after 14 days) without any significant changes of body weight of treated mice. Figure 7Chemical structure of the amphiphilic Platinum (IV) prodrug (ALN-PtIV-Lipo).68 Chemical structure of the amphiphilic Platinum (IV) prodrug (ALN-PtIV-Lipo).68 Li et al developed a versatile nanosystem by combining oxaliplatin (Oxa), PD-L1 antibody and zoledronic acid (ZA) for synergistic OS chemo- and immunotherapy.69 ZA is a third-generation nitrogen-containing bisphosphonate able to target the bone microenvironment and exerting vaccine adjuvant activities. A Pt (IV) prodrug strategy was exploited for the conjugation of Oxa with both a hexadecyl chain (C16) and a trimethylammonium ethyl amine group (Figure 8). The amphiphilic C16-Oxa-TEAI was able to self-assemble into nanoparticles (NP1); then electrostatic interactions with the bone-seeking ZA produced nanoparticle 2 (NP2) (Figure 8a). Upon reaching the acidic TME, released Oxa and ZA exhibited synergistic antitumor efficacy and induced stronger ICD effect, triggering a robust antitumor immune response since NP2 turned out to be able to reprogram the immunosuppressive TME and upregulated programmed death ligand 1 (PD-L1) expression on tumor cells surface. The pH-responsive and glutathione-responsive nature of NP2 contributed to the enhanced accumulation and controlled release of payload at the TME, while ZA increased the affinity for bone tumors with remarkable therapeutical efficacy against OS. The effects were evaluated upon intravenous administration on an orthotopic K7M2 OS model (Figure 8b) and, also, in a patient-derived xenograft OS model (PDXOS, Figure 8c) confirming the ability of NP2 to markedly suppress the growth of both orthotopic K7M2 tumors and subcutaneous PDXOS along with eliciting a strong activation of immune response. A pH-sensitive, fluorescence-labeled magnetic silica nanosystem (Cy7-labeled Fe3O4@MSNs) linked with the CXCR1 targeting peptide and loaded with cisplatin (Cis@MFPPC) was proposed to selectively target CXCR1 on OS circulating tumor cells (CTC).70 CXCR1 plays a critical role in tumor metastasis and drug resistance emerging as a therapeutic target for OS. The surface of MSNs was coated with polyacrylic acid to prevent burst drug release and provide pH sensitivity. In vivo biological results demonstrated that CTC survival was effectively inhibited by the targeted nanoparticles that, synergistically, were also able to inhibit OS growth and pulmonary metastasis in an orthotopic model and PDXOS. Figure 8Schematic illustration of the chemical components and the preparation of NP1 and bone-targeting NP2 (a); Biological mechanism of action: Inhibition of tumor growth on an orthotopic K7M2 OS model (b) and on a PDXOS model (c).69Notes: Reprinted from Nano Today, Vol 50, Li J, Liao S, Wu Y et al. Dual-responsive nanoparticles targeting bone microenvironment for synergistic chemoimmunotherapy of osteosarcoma by remodeling immune microenvironment. 101877, Copyright 2023, with permission from Elsevier.69 Schematic illustration of the chemical components and the preparation of NP1 and bone-targeting NP2 (a); Biological mechanism of action: Inhibition of tumor growth on an orthotopic K7M2 OS model (b) and on a PDXOS model (c).69 Ji et al developed oligopeptide-functionalized carbonate apatite nanoparticles loaded with cisplatin and indocyanine green (ICG) for NIR-II imaging guided multimodal OS targeted therapy.71 The CaCO3-ICG-DDP-PEG-PT nanocarrier (CIDP-PT) was synthesized using a gas dispersion method in the presence of CDDP. ICG and DSPE-PEG2000-COOH were also added during the synthesis with the double aim to endow the nanoparticles with NIR light absorption efficiency for photothermal therapy and to achieve prolonged circulation time, enhanced stability, and improved encapsulation efficiency. To promote OS targeting, the carboxyl group of DSPE-PEG2000-COOH was coupled to the oligopeptide to improve receptor-mediated binding to OS cells. The calcium carbonate matrix decomposed in the acidic TME to release calcium ions that interacted with ROS, promoting OS cells apoptosis and necrosis. The proposed multifunctional material combining synergistically NIR photoresponsive activity with platinum-based chemotherapy and tumor-targeting properties effectively reduced tumor volume in vivo while maintaining biocompatibility and safety. Yang et al assembled iron-polydopamine coated silica nanoparticles decorated with folic acid and loaded with CDDP (SiO₂@PDA/Fe³+-FA@CDDP) for treating chemoresistant (cisplatin-insensitive) OS by combining chemodynamic and photothermal therapy.72 These biocompatible multifunctional nanoparticles demonstrated high drug-loading capacity (DOX and CDDP loading of 21.25% and 23.80%, respectively), pH-sensitive release, rapid tumor accumulation (eight hours after injection) due to folate-mediated targeting, good photothermal conversion efficiency (57.63%), enabling localized heat generation under NIR irradiation. The presence of Fe3+ ions can activate the Fenton-like reaction in the acidic TME generating ROS that induce damage to organelles and DNA promoting apoptosis in cisplatin-resistant OS cells. The combination of chemodynamic and mild photothermal therapy effectively restores the sensitivity of OS cells to chemotherapy. The killing effect of SiO₂@PDA/Fe³+-FA@CDDP combined with NIR laser irradiation was also confirmed in vivo on the xenograft cisplatin-insensitive OS model comparing with the use of CDDP alone that was ineffective. MTX-Nanotherapeutics Metotrexate (MTX) is an antifolate drug with a chemical structure similar to folic acid enabling it to competitively inhibit the activity of the dihydrofolate reductase (DHFR).73 This enzyme catalyzes the reduction of folic acid to dihydrofolate (DHF) and subsequently to tetrahydrofolate (THF), essential cofactors for nucleotide synthesis. This inhibition compromises multiple aspects of folate metabolism inducing cell cycle arrest and apoptosis. Specifically, THF is converted into different metabolites such as 5,10-methylene-THF, 10-formyl-THF and 5-methyl-THF. 5,10-Methylene-THF serves as both a carbon donor and a coenzyme in the methylation process of 2-deoxyuridine-5-monophosphate (dUMP) to 2-deoxythymidine-5-monophosphate (dTMP). This critical reaction is catalyzed by the enzyme thymidylate synthase that is also directly inhibited by MTX and DHF. Furthermore, 5,10-methylene-THF is transformed into 5-methyl-THF that serves as a cofactor in the methylation of homocysteine to methionine via methionine synthase. Methionine is essential to produce S-adenosylmethionine, a universal methyl donor involved in DNA methylation. The depletion of 5-methyl-THF due to MTX treatment leads to elevated homocysteine levels and reduced methylation capacity, further contributing to the drug’s cytotoxic effect. 5,10-methylene-THF is also converted into 10-formyl-THF, a substrate involved in the de novo synthesis of purines. However, during DHFR inhibition, the concentration of 10-formyl-THF remains around 80% of its usual levels, highlighting that the primary inhibition of purine synthesis is related to elevated levels of DHF and the direct inhibition by MTX of two key enzymes: glycinamide ribonucleotide (GAR) transformylase (GART) and 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) transformylase (ATIC). Upon administration, MTX is quickly absorbed and transported into cells through the reduced folate carrier (RFC) primarily accumulating in erythrocytes where it is polyglutamated (MTX-PGs). MTX-PGs not only serves as a stored version of the drug but also exhibits a higher affinity for folate-dependent enzymes, enhancing its effectiveness. The most common adverse effects associated with MTX are bone marrow suppression, intestinal mucositis, renal and hepatotoxicity.74,75 MTX-PGs, which remain in cells for extended periods, contribute to liver toxicity by inducing oxidative stress through ROS production, leading to lipid peroxidation, depletion of antioxidants, and activation of pro-inflammatory pathways such as NF-κβ and JAK-STAT3. This results in hepatocellular damage, increased levels of liver enzymes (aspartate aminotransferase, AST; alanine aminotransferase, ALT) and activation of hepatic stellate cells promoting fibrosis. MTX resistance in OS involves several mechanisms. One key factor is the decreased expression of the RFC, which impairs MTX uptake into cells. Additionally, overexpression of DHFR, the main enzyme targeted by MTX, reduces the drug’s efficacy. Furthermore, increased activity of ABC transporters, such as multidrug resistance protein 1 (MDR1), enhances the efflux of MTX from cells, reducing its intracellular concentration and contributing to resistance.23 To address toxicity and resistance issues, nanosized MTX delivery systems for OS were developed based on nanoceramics, thermosensitive hydrogels, and tumor-derived microvesicles. Ray et al incorporated MTX into a nanoceramic matrix (Mg-Al-layered double hydroxide, LDH) producing LDH-MTX nanoparticles that were in turn encapsulated in PLGA to improve drug solubility and therapeutic efficacy and to avoid the typical burst release.76 The ability of PLGA-LDH-MTX nanohybrid to suppress tumor growth was evaluated in HOS-tumor bearing mice, focusing on pharmacokinetics, efficacy, survival rate, nephrotoxicity, hepatotoxicity, and tissue distribution. The results demonstrated a significant enhancement in therapeutic efficacy with tumor reduction reaching 81.26% compared to only 33.65% for free MTX. Furthermore, the safety of the nanohybrid was markedly improved as evidenced by a doubling of the LD50 value relative to free MTX. Toxicological assessments revealed normal serum levels of AST and ALT as well as stable blood urea nitrogen (BUN) and plasma creatinine (CRT) levels excluding hepatotoxic and nephrotoxic effects. The study of Shan et al described the development of an injectable thermosensitive hydrogel based on methoxy poly(ethylene glycol)-poly(L-valine) copolymer (mPEG45–PLV19) designed for local and controlled release of MTX and ALN to synergistically inhibit OS progression.77 The block copolymer was synthesized through ROP of L-valine-N-carboxy anhydride (L-Val NCA) using mPEG45-NH2 as a macroinitiator. The polymer underwent a sol-gel transition in PBS upon temperature increase forming a 3D network structure able to load MTX and ALN. Therefore, the in-situ gelation at the body temperature promoted a slow degradation and a localized release of drugs with a long-lasting effect on the affected area. In vitro and in vivo assays demonstrated good biocompatibility, although an initial inflammatory reaction was observed in vivo, which gradually subsided over time. Notably, the co-entrapped association of MTX and ALN into the injectable thermosensitive hydrogel turned out to be superior to free MTX and MTX+ALN in terms of antitumor efficacy, anti-bone destruction effect, lung metastasis inhibition and safety. A thermosensitive hydrogel made of PLGA-PEG-PLGA was designed for simultaneous local delivery of MTX, DOX, and CDDP.78 After an initial burst release in the first 2 days, a sustained drug release was observed over 10 days (about 80% of the drugs released from the hydrogels at day 11). However, since testing was performed only at pH 7.4, the system’s behavior in the acidic TME remains uncertain. Moreover, it is noteworthy that, based on the in vivo assays on a nude mice model bearing human OS Saos-2 xenograft, an effective tumor suppression was detected for up to 16 days suggesting that the in vitro drug release behaviors were different from those in vivo. Tumor suppression efficacy of DOX-, CDDP- and MTX- coloaded hydrogels was markedly enhanced compared to hydrogels loaded with single drug or with only two drugs. Histopathological analysis demonstrated that localized drug delivery effectively minimized systemic toxicity, particularly reducing nephrotoxicity and cardiotoxicity commonly associated with systemic administration of DOX, CDDP and MTX. Recently, MTX-loaded microvesicles (MV) derived from 143B and MG63 cells EphA2+ were proposed for the active targeting of ephrin alpha 2 receptor (EphA2), a tyrosine kinase receptor highly overexpressed in OS cells.79 After loading MTX, EphA2-MV/MTX were assembled and coated with carboxyl Fe3O4 superparamagnetic nanoparticles decorated with YSA peptide (YSA-SPION) exploiting the affinity of YSA peptide for EphA2. The final YSA-SPION-MV/MTX nanocomposite demonstrated an effective targeting effect on OS cells together with pH-sensitive drug release properties. In vitro and in vivo studies demonstrated greater efficacy compared to MV-MTX and free MTX, along with improved biosafety and reduced nephrotoxicity. However, although active targeting improved therapeutic performance, lung metastasis formation was still observed, albeit at a reduced rate. DTX-Nanotherapeutics Docetaxel (DTX) is a taxane anticancer agents that primarily targets β-tubulin on microtubules which are crucial for cell division. It facilitates microtubule assembly and reinforces their structure, preventing depolymerization and disrupting their natural dynamics. Unlike other antimicrotubule agents that block assembly, DTX stabilizes pre-formed microtubules. While it binds to the same site as Paclitaxel, it exhibits a higher affinity and greater efficacy in promoting tubulin polymerization. DTX also induces apoptosis by affecting the Bcl-2 gene family which plays a key role in cell survival. Specifically, DTX deactivates Bcl-2 through phosphorylation being significantly more potent than Paclitaxel in this regard -by a factor of 10 to 100- making it a more effective pro-apoptotic agent.80 The development of resistance to DTX poses a major challenge in cancer treatment. One key mechanism involves alterations in microtubules, where mutations in β-tubulin genes increased expression of β-tubulin isotypes III or IV, or post-transcriptional modifications can lead to structural changes that reduce the drug’s effectiveness. Another contributing factor is the presence of cancer stem cells, which, despite DTX-induced cell cycle arrest, can survive and develop resistance. Drug efflux ABC transporters also play a central role in resistance by actively expelling DTX from cancer cells. Impaired drug distribution further contributes to resistance, as the disorganized vasculature in solid tumors hinders the effective delivery of DTX. Hypoxia within tumors not only reduces drug uptake but also promotes the expression of survival genes, like hypoxia-inducible factor-1, making cancer cells more resistant. The TME, with factors like cytokines and growth factors, plays a crucial role as well in cancer cell survival and resistance. Additionally, the overexpression of factors like Interleukin-6 (IL-6) and Nuclear factor-κB (NF-κB) further contributes to resistance mechanisms. DTX treatment is associated with both acute and long-term side effects, which vary based on dosage and treatment schedule but can be managed between cycles or upon discontinuation. Acute adverse effects may include infusion reactions, febrile neutropenia, nail disorders, fluid retention, skin-related issues, pneumonitis, emesis and lacrimal duct complications. In the long term, it can lead to sensory and motor peripheral neuropathy. Besides these limitations, DTX also suffers from poor water solubility, low selective distribution, and rapid elimination. To the best of our knowledge, only a few in vivo studies of DTX-loaded delivery systems were reported in literature so far, and specifically, only one against OS. Zheng et al developed an injectable microspheres-embedded hydrogel matrix for the sequential release of combretastatin A4 (CA4), a vascular disrupting drug, and DTX (Figure 9).81 The hydrogel is based on the triblock copolymer poly(L-alanine-co-L-phenylalanine)-block-poly(ethylene glycol)-block-poly(L-alanine-co-L-phenylalanine) (PLAF-b-PEG-b-PLAF) prepared via ROP of L-alanine N-carboxyanhydride and L-phenylalanine N-carboxyanhydride, employing PEG-bis-amine as the macroinitiator. The DTX-loaded PLGA microspheres (MP/DTX) were assembled through a typical water-in-oil-in-water double emulsion followed by CA4 addition at 4°C, to obtain a homogeneous solution (Polypeptide sol, Figure 9). Release experiments demonstrated that CA4 was released from the hydrogel with an initial burst effect, while DTX exhibited a sustained release from the degrading microspheres. The in vivo treatment with the hydrogel-microsphere construct loaded with both CA4 and DTX efficiently suppressed tumor growth in mouse K7 OS compared to control groups. Histopathological analysis revealed that early CA4 release effectively disrupted tumor vasculature, creating interstitial spaces that facilitated deeper penetration of DTX into the tumor tissue to induce apoptosis. After peritumoral subcutaneous injection, the construct completely degraded in 42 days. Overall, the synergistic effect the dual-drug loaded system resulted in more effective tumor suppression (increased apoptosis and reduced tumor cells proliferation) than treatments with either drug alone or simultaneous delivery of both free drugs. Figure 9Schematic illustration of the preparation and biological effects of injectable PLGA microspheres-embedded PLAF-b-PEG-b-PLAF hydrogel loaded with DTX and CA4. Reprinted with permission from Zheng Y, Cheng Y, Chen J, et al. Injectable hydrogel–microsphere construct with sequential degradation for locally synergistic chemotherapy. ACS Appl. Mater. Interfaces 2017, 9, 4, 3487–3496.81 Copyright 2017 American Chemical Society. Schematic illustration of the preparation and biological effects of injectable PLGA microspheres-embedded PLAF-b-PEG-b-PLAF hydrogel loaded with DTX and CA4. Reprinted with permission from Zheng Y, Cheng Y, Chen J, et al. Injectable hydrogel–microsphere construct with sequential degradation for locally synergistic chemotherapy. ACS Appl. Mater. Interfaces 2017, 9, 4, 3487–3496.81 Copyright 2017 American Chemical Society. GEM-Nanotherapeutics Gemcitabine (GEM, 2’,2’-difluorodeoxycytidine, dFdC) is a deoxycytidine nucleoside analogue bearing two fluorine atoms into the deoxyribose ring. As a prodrug, it is initially inactive and requires intracellular activation to exert its pharmacological effects, which include inducing cell death preventing the transition from the G1-phase to the S-phase. To enter and exit the cell, GEM relies on complex transport systems involving several membrane proteins (human nucleoside transporters, hNTs), known as equilibrative nucleoside transporters (ENTs) and concentrative nucleoside transporters (CNTs) that differ according to mechanisms of transport. After entering the cell, GEM, similarly to other inactive nucleoside analogues, must undergo intracellular phosphorylation into its mono- (dFdCMP), di- (dFdCDP), and tri-phosphorylated (dFdCTP) derivatives (Figure 10) to become active.82 Afterwards, GEM can interact with DNA polymerase integrating into the growing DNA strand and halting further elongation; specifically, once incorporated, only one additional nucleotide can be added before synthesis is irreversibly blocked. The cell’s normal repair mechanisms fail to remove dFdCTP leading to DNA synthesis inhibition, loss of division capacity, and eventual apoptosis. This process, known as masked chain termination, allows GEM to evade cellular repair systems. Figure 10Intracellular activation and mechanism of action of GEM. Intracellular activation and mechanism of action of GEM. GEM cytotoxicity is also influenced by a self-potentiation effect due to inhibition of key enzymes (Figure 10) leading to the depletion of nucleotide pools.82 One of the major contributors to this self-potentiation mechanism is GEM’s diphosphate metabolite, dFdCDP, which acts as a potent inhibitor of ribonucleotide reductase (RNR) that converts ribonucleotides into deoxyribonucleotides, a crucial step for DNA replication. RNR inhibition produces a reduction in the intracellular deoxynucleotide triphosphate (dNTP) pool. Additionally, dFdCTP can inhibit dCMP deaminase, an enzyme responsible for converting dFdCMP into dFdUMP. dFdUMP itself contributes to GEM self-potentiation by inhibiting thymidylate synthase (TS), the enzyme responsible for converting deoxyuridine monophosphate (dUMP) into thymidine monophosphate (dTMP). By blocking TS activity, dFdUMP directly effects the dNTP pool, further affecting DNA synthesis, reinforcing GEM cytotoxic effects. The inactivation of GEM relies on three key mechanisms that counteract its cytotoxic properties. The primary inactivation pathway is driven by deoxycytidine deaminase (dCDA), an enzyme that deaminates GEM converting it into the inactive 2’,2’-difluorodeoxyuridine (dFdU). Although dCDA exhibits a lower affinity for GEM compared to its natural substrate, deoxycytidine, it still plays a significant role in reducing the drug’s potency. Research indicates that overexpression of dCDA enhances resistance to GEM, while inhibiting this enzyme can restore drug sensitivity.83 Another mechanism involves 5’-nucleotidase (5’-NT) which reverses the phosphorylation of dFdCMP converting it back into its inactive form. This process opposes the activation of GEM by deoxycytidine kinase (dCK). The third inactivation pathway is regulated by dCMP-deaminase that converts dFdCMP into dFdUMP, reducing the available pool of active drug.84 Although considered the primary chemotherapeutic drug for advanced or metastatic pancreatic cancer, GEM’s effectiveness is limited by its rapid metabolism, high dosage, drug resistance, and adverse side effects. Moreover, GEM is listed as second line therapy option for OS, with or without DTX, in the NCCN Guidelines of the United States;7 specifically, the combination of GEM and DTX is often used to treat patients with recurrent OS. To address mentioned challenges and improve the safety profile, various approaches have been recently tested including GEM-prodrugs,85 co-formulation of GEM with other anticancer drugs and the use of nanocarriers such as polymeric nanoparticles, liposomes, and hydrogels.86 A PLGA-based nanocarrier conjugated with zoledronic acid (ZA) was designed to enhance the targeted delivery of GEM and epirubicin (4′-epimer of DOX) to OS cells.87 PLGA was covalently coupled with ZA using CDI and subsequently formulated into nanoparticles (PLGA-ZANPs) through solvent diffusion or nanoprecipitation. PLGA-ZOL NPs were loaded with either GEM (PZ-1), epirubicin (PZ-2), or both drugs (PZ-3). TEM images revealed spherical NPs uniformly distributed without agglomeration, with size ranging from 142 to 245 nm and a positive zeta potential between 22.4 and 26.5 mV, indicating good colloidal stability. Stability studies across different pH showed that the NPs structural integrity was maintained, with PZ-3 exhibiting unimodal size distribution between pH 3.5 and 8.0. Encapsulation efficiency was high, with values of 80.2% for PZ-1, 82% for PZ-2, and 89% for PZ-3, while the corresponding drug loading were 27.3%, 29.2%, and 33.2%, respectively. Drug release studies demonstrated that epirubicin diffused faster than GEM (45% vs 25% released within 24 h) at physiological conditions (pH 7.4). However, drug diffusion was slower and sustained at pH 4.5 (the pH of the TME), with 25% epirubicin and 15% GEM released in the same period. The release from PZ-3 was prolonged lasting up to 80 h at physiological pH and extending to 120 h in acidic conditions. PZ-3 was tested in vivo on Sprague-Dawley rats bearing MG-63 OS cells demonstrating greater efficacy in reducing tumor volume compared to PZ-1 and PZ-2. Furthermore, epigenetic regulations by PZ-3 were also detected (downregulation of miR-10b and miR-21 oncomirs; upregulation of tumor suppressor miR-34a) requiring further evaluations. Rodríguez-Nogales and coworkers proposed nanoassemblies (NAs) composed of equimolar alkyl-lysophospholipid edelfosine (EF) and squalenoyl-GEM (SQ-Gem) for treating high-grade pediatric OS.88 EF is a drug that induces apoptosis by activating the Fas/CD95 cell death receptor or inhibiting the MAPK/ERK and Akt/protein kinase B survival pathways, without directly damaging DNA, hence favouring a better life quality for pediatric OS patients. GEM was covalently bound to squalenic acid via amide coupling and subsequently nanoformulated by nanoprecipitation into SQ-Gem/EF NAs of about 50 nm. The nanocomposite was tested in vivo by intratibial injection in rats implanted with P1.15 OS cells. The co-assembly of SQ-Gem with EF significantly modified the pharmacokinetic profile of GEM in vivo reducing the amount of GEM in the bloodstream compared to SQ-Gem NAs alone. Additionally, drug released from SQ-Gem/EF NAs showed a prolonged presence in the bloodstream extending up to 8 h. In terms of tolerability, the SQ-Gem/EF NAs exhibited significantly better safety compared to the SQ-Gem NAs. While the SQ-Gem NAs triggered severe toxicity resulting lethal for 85% of the mice after the second administration, SQ-Gem/EF NAs did not cause any fatal adverse events, suggesting that the co-assembly with EF improved the therapeutic window. Importantly, there were no significant changes in body weight in the SQ-Gem/EF NAs group, indicating good tolerability after multiple administrations. Regarding anticancer efficacy, SQ-Gem/EF NAs demonstrated superior tumor inhibition compared to free GEM in a P1.15 orthotopic OS tumor model, reducing tumor growth by 2.92 times compared to the control group, while free GEM only showed a 1.70 times reduction. Moreover, histological analysis revealed fewer metastatic lesions in the lungs for the SQ-Gem/EF NAs group compared to free GEM group, indicating the improved potential of the SQ-Gem/EF NAs formulation in reducing metastasis. Lastly, the toxicity evaluation showed no significant renal or hepatic disruptions in the SQ-Gem/EF NAs treatment group. Hematological analysis revealed that the SQ-Gem/EF NAs did not significantly affect red blood cell counts, and neutrophil counts were less reduced compared to free GEM treatment. Overall, SQ-Gem/EF NAs exhibited improved pharmacokinetics, reduced toxicity, enhanced anticancer efficacy and safety profile compared to the free drug, although a lower anticancer profile was observed in vitro compared to free GEM. To achieve local GEM release, Wu et al developed a smart multifunctional implant based on in situ photocrosslinkable hydrogel composed of GEM-loaded liposomes combined with gelatin methacryloyl (GEM-Lip@Gel).89 The GEM-Lip@Gel hydrogel exhibited good mechanical strength and stability and a sustained drug release for about 4 days, compared to the short half-life of 32–94 min of GEM. The in vitro and in vivo testing in MG63 tumor-bearing Balb/c mice model revealed increased antitumoral activity compared to the positive control group treated with free GEM. A multifunctional nanoplatform based on the natural H-ferritin (HFn) encapsulating GEM and the photosensitizer IR-780 (HFn@Gem/IR-780) was recently proposed to enhance the treatment of metastatic and recurrent OS by integrating multiple therapeutic approaches, including chemotherapy, photothermal, photodynamic, and chemodynamic therapy.90 The fluorescent dye IR-780 serves as both a photosensitizer and a photothermal agent, producing ROS and heat when exposed to NIR light. HFn is a ferritin-derived protein that naturally self-assembles into a nanocage with an internal diameter of 8 nm, enabling targeted drug delivery as it is recognized by transferrin receptor 1 (TfR1) highly expressed in tumor cells. Upon cellular uptake, the Fe₂O₃•H₂O component within HFn disintegrates in the lysosomal environment, releasing Fe2+ ions that initiate the Fenton reaction, further increasing ROS levels through chemodynamic therapy. This surge in ROS induces lipid peroxidation and depletes glutathione, two essential processes in ferroptosis. By combining these therapeutic strategies, this nanoplatform aimed to overcome tumor resistance, achieving a synergistic effect. The validity of this approach was confirmed through in vitro studies on HOS, MG-63, and K7M2 cells, as well as in vivo experiments in male BALB/c mice bearing K7M2 tumors, showing improvement in cytotoxicity compared to the free drug. Importantly, HFn@Gem/IR-780 was found to have a safe toxicological profile, as evidenced by the absence of pathological abnormalities in major organs and by the normal levels of blood biochemical markers. Since the liver is a primary site for HFn metabolism, iron ion levels were measured revealing no excessive accumulation in liver cells of tumor-bearing mice, suggesting that TfR expression in OS cells is significantly higher than in normal cells, allowing for selective tumor targeting. New Frontiers in OS Immunotherapy During OS genesis, a key alteration of the bone tissue microenvironment is the infiltration of immune cells, including macrophages, neutrophils, dendritic cells, mast cells, natural killer cells, T and B lymphocytes. Their imbalance is considered as a crucial factor to modulate OS progression and metastasis.91 Extensive immune cell infiltration leads to a complex microenvironment that support OS cells growth by establish an immunosuppressive niche promoting their proliferation.92 Cancer immunotherapy is an attractive therapeutic strategy under clinical settings aiming to inhibit tumor growth and metastatization by intervening in the immune response process, avoiding drug resistance and immune escape to a large extent and reducing off-target adverse effects. Immunotherapy has recently produced encouraging therapeutic responses in melanoma, prostate cancer, renal cell carcinoma, and non-small-cell lung cancer becoming a FDA-approved reality.93 The heterogeneity and immunosuppressive properties of OS TME make immunotherapy not yet approved for OS. Nevertheless, recent advances, including monoclonal antibodies, tumor vaccines, immunomodulators, genetically modified T cells, cytokines, immune cell therapies, immune checkpoint inhibitors, and oncolytic viruses have been tested in preclinical and clinical trials, bringing hope for the future. In this context, the “immune cocktail therapy” combining multiple immunotherapeutics holds great promises and has been well summarized in recent reviews.13,91,94–96 Mifamurtide (liposomal muramyl tripeptide phosphatidylethanolamine (L-MTP-PE), Figure 11) is used in addition to standard OS chemotherapy for children and adolescents as a nonspecific immunomodulator able to activate macrophages and monocytes through interaction with the NOD2 receptor (nucleotide-binding oligomerization domain 2) for immune response. Mifamurtide is associated with a significant improvement in 6-year survival in young patients with curable OS. From a chemical point of view, it is a liposomal formulation of the active ingredient MTP-PE, a synthetic analog of the muramyl dipeptide, a component of bacterial cell wall. Mifamurtide has been approved in Europe by EMA (trade name Mepact®, marketed by Takeda) since 2009 for the treatment of non-metastatic OS after surgical resection in combination with postoperative multi-agent chemotherapy in patients aged 2–30 years; whereas no approval from US Food and Drug Administration has yet been provided.97,98 Figure 11Chemical structures of mifamurtide, anti-angiogenic multi-RTK inhibitors (pazopanib, sorafenib, regorafenib, anlotinib, lenvatinib, cabozantinib) and everolimus. Chemical structures of mifamurtide, anti-angiogenic multi-RTK inhibitors (pazopanib, sorafenib, regorafenib, anlotinib, lenvatinib, cabozantinib) and everolimus. Anti-angiogenic multi-Receptor Tyrosine Kinase (RTK) inhibitors (including pazopanib, sorafenib, regorafenib, anlotinib, lenvatinib and cabozantinib, Figure 11)99 have been trialed in OS showing some clinical efficacy in combination with chemotherapy. These agents exhibit potent anti-angiogenic activity by inhibiting vascular endothelial growth factor receptors (VEGFRs), while simultaneously targeting other key RTKs involved in OS progression, such as platelet derived growth factor receptors (PDGFRs), c-KIT, fibroblast growth factor receptors (FGFRs), RET, and/or MET proto-oncogenes. Sorafenib, regorafenib and cabozantinib are included as second line therapy options for recurrent OS in the NCCN Guidelines of the United States.7 However, regorafenib is not approved by EMA for sarcomas other than advanced/metastatic gastrointestinal stromal tumor in later treatment lines. Furthermore, the combination of sorafenib and everolimus (Figure 11), inhibitor of mTOR pathway, has demonstrated activity in patients with relapsed and inoperable high-grade OS, unfortunately without affecting significantly the dismal prognosis.100 Overall, immunotherapy appears as a promising strategy for treating OS in combination regimens, harnessing the power of the immune system to target and destroy tumor cells. The major challenge lies in the modulation and remodeling of the immunosuppressive OS microenvironment owing to strong genomic heterogeneity across patients. Gene Therapy for OS Treatment Considering that genetic mutation is one of the most fundamental factors of OS pathogenesis, it is expected that a proper combination of gene therapy and conventional therapies might achieve better disease control. Gene therapy offers several advantages for treating inherited disorders, infections, and cancer by using exogenous nucleic acid molecules as drugs, including microRNA (miRNAs), short interfering RNA (siRNAs), messenger RNA (mRNAs) and also the CRISPR/Cas genome editing system.101 In cancer treatment, gene therapy might allow for targeting specific genomic mutations, having less resistance compared to traditional approaches and enabling personalized interventions. Moreover, effective gene therapy requires reliable delivery systems (ie, viral or non-viral vectors) to face common challenges including poor intracellular uptake, rapid serum and enzymatic degradation rate, fast renal clearance and quick phagocytic uptake, which can hinder therapeutical efficiency.101 OS patients undergoing extensive surgery and chemotherapy result in dysregulated bone homeostasis that significantly hinder the bone’s ability to regenerate and remodeling. Actually, a delicate balance exists between promoting bone remodeling and suppressing tumor growth (Figure 12) which has considerably slowed clinical translation of tissue engineering approaches for OS treatment.102 Figure 12Schematic illustration of the dual synergistic potential of miR-29b to induce apoptosis and to promote bone homeostasis and re-modeling.103Notes: Reproduced with permission from Freeman FE, Dosta P, Shanley LC, et al. Localized Nanoparticle-Mediated Delivery of miR-29b Normalizes the Dysregulation of Bone Homeostasis Caused by Osteosarcoma whilst Simultaneously Inhibiting Tumor Growth. Adv Mater. 2023;35:e2207877. © 2023 The Authors. Advanced Materials published by Wiley-VCH GmbH.103 Schematic illustration of the dual synergistic potential of miR-29b to induce apoptosis and to promote bone homeostasis and re-modeling.103 In this regard, miRNAs may offer valuable benefits by simultaneously targeting tumor suppression and promoting bone remodeling.104 Specifically, miR-29b plays a key role in bone regeneration promoting osteoblast differentiation (by downregulating TGF-3 signaling) and inhibiting angiogenesis (by targeting VEGF signaling pathways). In this framework, a recent study of Freeman et al introduced, for the first time, the therapeutic potential of miR-29b in blocking OS tumor growth exploiting a hyaluronic acid-based hydrogel as delivery vehicle (Figure 12).103 An injectable formulation of poly-beta-amino-esters (pBAE) nanoparticles delivered by a hyaluronic-based hydrogel enabled local and sustained release of miR-29b at the primary tumor site improving the antitumoral efficacy and suppressing tumor growth while simultaneously facilitating the repair of the surrounding damaged bone even during chemotherapy. The therapeutic potential was tested in vivo in a metastatic murine model showing that when miR-29b was delivered along with systemic DOX chemotherapy provided a significant reduction in tumor volume (45%) compared to chemotherapy alone, an increase in mouse survival (50% survival went from 24 days to 32 days), and a significant reduction (75%) in osteolysis, whilst normalizing the dysregulation of bone homeostasis caused by tumor growth. Overall, this work addressed a pivotal science question, the balance between inducing bone regeneration and promoting OS elimination (also preventing tumor recurrence) and highlighted how gene therapy can contribute to OS treatment in combination with standard chemotherapy. During OS development, the expression of miR-22 is significantly down-regulated. Therefore, miR-22 is a promising therapeutic target since its restoring can suppress tumors and contribute to bone remodeling by enhancing osteoblast differentiation. In this regard, Chen et al developed redox-sensitive positively charged polymeric nanoparticles to deliver both miR-22 and volasertib into OS cells (TC/miR-22 NPs).105 Volasertib is a Polo-like kinase 1 (PLK1) inhibitor able to reduce OS proliferation both in vitro and in vivo. The reduction-responsive polyhydroxy cationic gene nanocarrier was prepared via a one-pot epoxy ring-opening reaction of 1,3,5-triglycidyl isocyanurate with cystamine or 1,6-hexanediamine. The strong binding ability of cationic nanoparticles prevented miR-22 from enzymatic and endo-lysosomal degradation and remarkably improved the transfection efficacy. The presence of disulfide bonds imparted responsiveness to the reductive environment typical of tumor cells. In vivo experiments in animal models of orthotopic OS, specifically in patient-derived chemo-resistant and chemo-intolerant patient-derived xenograft (PDX) models, demonstrated that the combined delivery of miR-22 along with volasertib suppressed tumor growth, reduced lung metastasis risk and overcame chemotherapy resistance. The study also revealed that miR-22 and volasertib synergistically inhibit the PI3K/Akt signaling pathway suppressing proliferation and promoting OS cell apoptosis. Since PLK1 is overexpressed in OS promoting cancer cell proliferation, it is considered as a powerful therapeutic target. A recent study suggested that the use of siRNA siPLK1-based nanoparticles reduced PLK1 gene expression resulting in cell cycle arrest and apoptosis, which in turn contributes to OS suppression.106 Positively charged nanoparticles based on CO2-based poly(vinylcyclohexene carbonates) (CPCHCs, Figure 13) with different positive charge densities (CPCHC46, CPCHC60, and CPCHC70) were synthesized through ring-opening copolymerization of CO2, cyclohexene oxide, and 4-vinyl-1,2-cyclohexene oxide and a thiol-ene reaction with 2,2-dimethoxy-2-phenylacetophenone as the photoinitiator. CPCHC60 was selected to deliver siPLK1 due to limited cytotoxicity and good transfection efficiency. The high density of positive charges contributed to nanoparticles stability, improved the loading of siRNA, shielding it from enzymatic and lysosomal degradation, and enhanced transfection efficiency. The CPCHC/siPLK1 nanoparticles effectively down-regulated the expression of the PLK1 gene, significantly blocked the G2/M phase of tumor cells and induced apoptosis resulting in tumor regression both in vitro and in vivo. Figure 13Schematic illustration of the chemical components and preparation of CPCHCs/siRNA nanoparticles and their roles in mediating siPLK1 uptake and PLK1 gene silencing in OS cells.106Notes: Used with permission from Li M, Lin ZI, Yang J, et al. Biodegradable carbon dioxide-derived non-viral gene vectors for osteosarcoma gene therapy. Adv Healthc Mater. 2023;12:e2201306. Copyright 2023, Wiley-VCH.106 Schematic illustration of the chemical components and preparation of CPCHCs/siRNA nanoparticles and their roles in mediating siPLK1 uptake and PLK1 gene silencing in OS cells.106 Combining siRNA-based gene therapy with other treatments is also gaining recognition as a prominent approach to treating OS. By considering highly overexpressed genes in OS, Samal and co-workers developed lipid-derived extracellular vesicles (EV) extracted from mouse OS cell line K7M2 and normal mouse preosteoblasts cell line MC3T3-E1 for the combined delivery of Hdac1-siRNA and zoledronic acid, as a bone resorption inhibitor.107 The surface of the EV was functionalized with folic acid for targeting purposes using a self-assembly insertion method by mixing a 1:1 ratio of DSPE-PEG-FA with EV, while the co-loading of zoledronic acid and Hadc1-siRNA was achieved by electroporation. These folate-decorated EV efficiently silenced Hdac1 genes associated with OS tumor progression and amplified the antitumor efficacy significantly reducing tumor volume without toxicity or damage to the major organs. Similarly, polydopamine nanoparticles coated with stem cell membranes and loaded with siRNA-targeting STAT3 and curcumin were developed for a synergistic combination of gene- and chemotherapy.108 STAT3 is a crucial regulator of OS progression, associated with poor clinical prognosis. The proposed nanoparticles owned a high siRNA loading efficiency, tumor-homing, and good stability, exerting both the anticancer effect of CUR and the gene expression silencing effect of STAT3 siRNA. Pre-clinical studies revealed good antitumoral effects on OS cell growth triggering apoptosis and good antitumor effects in the OS-bearing mouse model, without side effects in major organs. Biomimetic PLGA nanoparticles loaded with DOX and survivin siRNA were successfully coated with mesenchymal stem cell membranes (DOX/siSUR-PLGA@MSCM) to have tumor-homing and immune escape abilities, enriching their localization at the tumor site.109 siRNAs targeting the apoptosis suppressor gene survivin inhibited the expression of survivin in tumor cells promoting apoptosis, thus producing a synergistic effect with DOX. The nanoparticles effectively inhibited tumor progression in MG63 tumor-bearing mice. Cao et al developed a cell-penetrating peptides (CPPs)-modified chitosan as a coating for functional nanoparticles that were produced exploiting the coordination between ferrous ions and siRad18 to encapsulate DOX.110 The nanoparticles based on a Fe-siRad18-DOX core and covered with CPP-chitosan were integrated in thermosensitive PLGA-PEG-PLGA hydrogel for peritumoral injection. This multifunctional system turned out to be able to induce apoptosis and ICD mediated by DOX, to upregulate Fe2+-mediated ROS generation and to effectively silence the crucial target gene Rad18. Concurrently, the Fe2+-mediated Fenton reaction and siRad18 collaboratively inhibit DNA damage repair mechanisms that usually provide resistance to DOX-induced cytotoxicity. The nanoparticles effectively inhibited OS progression in vivo mitigating lung metastasis and, when used in combination with a PD-L1 monoclonal antibody (αPD-L1), enhanced the anti-tumor immune response. The limitation of this study, by the authors’ own admission, lies in the lack of comprehensive analysis on the pathways through which the proposed system synergistically improves therapeutic outcomes. Overall, although gene therapy has achieved great progress and holds valuable promise for the future, the genomics-driven management of OS is still in the experimental arena, therefore a long way is paved from actual clinical application. Translational Challenges and Solutions The data above discussed are presented in this section in Tables 2–5 from the carrier’s perspective. Analysis of the Tables points out that liposomes are the only carriers that have undergone preclinical-to-clinical translation, whereas other Nanotherapeutics remain confined to the preclinical stage. Therefore, a concerted effort from researchers is needed to identify bottlenecks that are often overlooked in literature and to address challenges and weaknesses in order to drive meaningful progress. Table 2Nanoscale Drug Delivery Systems Based on Liposomes Tested in vivo for OS TreatmentType [Ref]TargetCargoClinical/PreclinicalEfficacySafetyPEGylated liposomes (Duomeisu®)38PassiveDOX + CDDPPhase I clinical trial (15 patients enrolled; 21-day cycle)Promising clinical activity in advanced OS, but phase II not yet carried outSafe profile. Reduced DOX cardiotoxicityALN-HA-SS-L/DOX Liposomes39Active:Bone (ALN);CD44 (HA)DOXPreClinical: MG-63in Balb/c miceRedox-responsiveness.Coadministration of RGD peptide improved tumor penetration and efficacyReduced DOX cardiotoxicity and lung metastasesHA-Lsdox Liposomes40Active:CD44 (HA)sDOX (H2S-donor DOX)PreClinical: K7M2in Balb/c miceEffective formulation against DOX-resistant Pgp-overexpressing OS where the rate of failure of the first-line chemotherapy is highSame cardiotoxicityprofile as Caelyx®LDL-decorated liposomes41Active:LDL receptor(via statin pre treatment)DOXPreClinical: U2OS-DX580in Balb/c miceIncreased DOX uptake.Effective reduction of tumor growth in DOX-resistant Pgp-overexpressing OSReduced DOX cardiotoxicityHLCN liposomes61Active:CD44 (HA)CDDP + siNrf2PreClinical: U2OSin Balb/c mice4x higher cytotoxicity vs liposomal CDDP (IC50 1 µM vs 4 µM)Minimal systemic toxicityLiposomal mifamurtide (L-MTP-PE)97,98Active:NOD2MTP-PEClinical use(2–30 years patients)Immunomodulator: coadministration with standard chemotherapy for the postoperative treatment of patients (2–30 years).Up to 6-year survival in non-metastatic OSEMA-approved(No FDA)10 times less toxic than MTP-PE Table 3Drug-Loaded Hydrogels Tested in vivo for OS TreatmentType [Ref]TargetCargoAnimal ModelEfficacySafetyBP/DOX/CS hydrogel43Local tumor siteDOXK7M2wtin Balb/c miceSynergistic photothermal chemotherapy.Phosphorus promoted bone regenerationNo systemic toxicityBPNSs-PEG-FA hydrogel44Folate receptorDOXK7M2wtin Balb/c miceSynergistic photothermal chemotherapy.pH responsiveness.Phosphorus promoted bone regenerationSafe profileSLP peptide hydrogel45Intratumoral injectionDOXK12 in Balb/c miceStrong efficacy compared to free DOXReduced off-site distributionGOMP hydrogel46Local tumor site(subcutaneous implant)DOX + PPy-PVP NPs143B in Balb/c miceSynergistic photothermal chemotherapy. Montmorillonite‑strontium (MMT-Sr) promoted bone regenerationNo side effects. In vivo degradation performance to be exploredAgarose/Fe-GA NPs hydrogel47Local tumor siteDOXK7M2wt in Balb/c miceSynergistic photothermal chemotherapy.No systemic toxicity (normal indexes of liver, kidney and blood)Ti6Al4V implant in PLGA-PEG-PLGA hydrogel63Local bone implantCDDP143B in Balb/c mice andStronger effect over the traditional systemic cisplatin delivery.Bone repair: bone in-growth and osseointegration early (4 weeks), but not later (8 weeks), after transplantation.Low systemic toxicity (negligible organ damage). Clinically approved materials: significant potential for clinical translationPLGA-PEG-PLGA hydrogel 64Local injectionDOX + CDDPHuman Saos-2 in Balb/c miceSynergistic anti-tumor efficacy of DOX and CDDPLow systemic toxicityGC-HP-β-CD hydrogel65Local injectionDOX + CDDPHuman bone KHOS/NP in Balb/c miceSynergistic effect of DOX and CDDPNo cardio-/nephrotoxicityPAMB-G-TK hydrogel loaded with Cis/Mn@Lipo-IL11 liposomes67Interleukin 11 receptor alpha (IL11Rα)CDDP + MYC inhibitor (NHWD-870)143B and K7M2 in Balb/c miceChemodynamic and immunotherapy combination. Modulation of immunesuppressive TME. Lung metastasis attenuationNo systemic toxicitymPEG45-PLV19 hydrogel77Local injectionMTX + ALNK7M2 in miceTumor suppression with minimal lung metastasis and minimal bone destruction.Well tolerated, mild transient inflammationPLGA-PEG-PLGA hydrogel78Peritumoral injectionMTX + DOX + CDDPSaos-2 in Balb/c miceHigh tumor suppression for up to 16 days, enhanced tumor apoptosis, increased regulation of apoptosis-related genes expressionNo systemic toxicityPLAF-b-PEG-b-PLAF + PLGA hydrogel81Peritumoral subcutaneous injectionDTX + CA4 (combretastatin A-4)K7M2 in Balb/c miceSynergistic effectTransient inflammation. Fully degraded after 42 days; no adverse effectsGEM-Lip@Gel hydrogel89ImplantGEMMG63- in Balb/c miceImproved antitumor effect compared to control groupsLimited inflammation.No adverse effectspBAE NPs in HA hydrogel103Peritumoral injection (hydrogel) + systemic DOXmiR-29b+ DOXK7M2 in metastatic Balb/c miceAntitumor and pro-osteogenic (normalizing bone homeostasis) dual effect. Increased survivabilitySafeCPP-chitosan coatedFe-siRad18-DOX NPsin PLGA-PEG-PLGA hydrogel110Peritumoral injectionDOX + siRad18+ PD-L1 monoclonal antibody(αPD-L1)K7M2 in Balb/c miceSynergistic gene, immuno- and chemotherapy. Enhanced ICD. Rad18 gene silencing (impeding DOX resistance).Lung metastasis mitigationNot specified Table 4Drug-Loaded Nanoparticles Tested in vivo for OS TreatmentType [Ref]TargetCargoAnimal ModelEfficacySafetyHA NPs62CD44DOX + CDDP + resiquimod (R848)K7M2 in Balb/c miceSynergistic immunochemotherapy. Lung metastasis inhibitionNo obvious organ damage or only slight organ damageAL-PtIV-Lipo NPs (PtIV prodrug)68Bisphosphonates (AL) target hydroxyapatite of boneALN + PtIVK7M2 in Balb/c miceTumor growth inhibition (TGI): 86% after 14 daysWell toleratedC16-Oxa-TEAI NPs (oxaliplatin prodrug)69Bisphosphonates (ZA) target bone microenvironment and exert vaccine adjuvant activitiesOxaliplatin + ZA in combination with PD-L1 mono antibodyK7M2 in Balb/c mice and PDXOSSynergistic chemoimmunotherapyExcellent histocompatibilityCy7-labeled Fe3O4@MSNs70CXCR1 peptide on OS circulating tumor cells (CTCs)CDDPSaos-2 in nude mice and PDXOSReduced CTC survival, tumor growth, and pulmonary metastasisNot determinedCaCO3-ICG-DDP-PEG-PT (CIDP-PT) NPs71Oligopeptide receptor-mediated targetingCDDP + ICG (NIR dye)143B in Balb/c micePhoto-chemo therapy; reduced tumor volume and burdenAbsence of structural damage to the major organsSiO₂@PDA/Fe³+-FA NPs72Folate receptorCDDPMNNG/HOS-NSC (not sensitive to cisplatin) in Balb/c miceChemodynamic and photothermal therapy (NIR irradiation)No organ toxicity (liver, lungs, and kidneys)PLGA-LDH NPs76Passive accumulationMTXHOS in Balb/c miceSignificant suppression of OS growth. Increase of survival rateNo notable body weight (systemic toxicity) changes till 40 mg/kg. Body weight decrease with ≥ 60 mg/kg. No nephro- and hepatotoxicity.PLGA-ZOL NPs87Bisphosphonates (ZA) target bone microenvironment and exert vaccine adjuvant activities.GEM + EPIMG63 in Sprague-Dawley ratsGreat efficacy in reducing tumor volume along with epigenetic changes affecting microRNA expressionsNot reportedSQ-Gem/EF NAs88Passive accumulationGEM + EF (pro-apoptotic drug)P1.15 in Balb/c miceDecreased primary tumor growth kinetics. Reduced number of lung metastasesNo significant renal/hepatic toxicity; lower neutropenia than free GEMHFn@Gem/IR-78090TfR1 receptorGEM + IR-780 (photosensitizer)K7M2 in Balb/c miceChemotherapy, photothermal, photodynamic, and chemodynamic therapyNo significant abnormalities observed in major organs and normal levels of blood biochemical markersTC/miR-22 NPs105PLK1miR-22 + VolasertibSaos-2 in nude mice, PDXOS and drug-resistant PDX modelsSuppression of tumor growth, reduction of lung metastasis risk. Overcame chemotherapy resistanceNot reportedCPCHCs NPs106PLK1siPLK1MNNG-HOS CDX in Balb/c miceSignificant tumor volume inhibitionNo toxic and side effectsPolydopamine NPs coated with stem cell membranes108STAT3siSTAT3 + curcuminMG63 in Balb/c miceExcellent antitumor effect No side effects in major organsPLGA NPs coated with mesenchymal stem cell membranes109SurvivinDOX + siSurvivinMG63 in Balb/c miceSynergistic effectNo toxicity Table 5Drug Delivery Systems Based on Exosomes and Vesicles Tested in vivo for OS TreatmentType [Ref]TargetCargoAnimal ModelEfficacySafetyExosomes (Exo-DOX)51Active: SDF1-CXCR4 axisDOXMG63 in Balb/c miceSynergistic effect of Exo and Dox: 6-fold reduction of tumor volume at day 21 compared with free DOXReduced cardiotoxicityHybrid Exosomes (HE/DOX)52Passive: Acidic TMEDOX143B in nude miceMore successful therapeutic effect than free DOX and liposomal DOXNot evaluatedExosome Mimetics (EM/DOX)54Passive: Acidic TMEDOX143B in Balb/c miceStronger inhibitory effect compared to free DOX and liposomal DOXReduced off-target toxicityMicrovesicles derived from tumor cells (YSA-SPION-MV/MTX)79Active: EphA2 receptorMTX143B in Balb/c miceTumor weight and volume significantly reduced. Lung metastasis inhibitionNo tissue damage in major organs from histological analysis. Only minor renal tissue damageExtracellular Vesicles (EV) derived from OS cells and preosteoblasts107Active: Folate receptorHdac1-siRNA + ZAK7M2 in Balb/c miceReduce tumor burdenNo tissue damage in major organs from histological analysis Table 2Nanoscale Drug Delivery Systems Based on Liposomes Tested in vivo for OS TreatmentType [Ref]TargetCargoClinical/PreclinicalEfficacySafetyPEGylated liposomes (Duomeisu®)38PassiveDOX + CDDPPhase I clinical trial (15 patients enrolled; 21-day cycle)Promising clinical activity in advanced OS, but phase II not yet carried outSafe profile. Reduced DOX cardiotoxicityALN-HA-SS-L/DOX Liposomes39Active:Bone (ALN);CD44 (HA)DOXPreClinical: MG-63in Balb/c miceRedox-responsiveness.Coadministration of RGD peptide improved tumor penetration and efficacyReduced DOX cardiotoxicity and lung metastasesHA-Lsdox Liposomes40Active:CD44 (HA)sDOX (H2S-donor DOX)PreClinical: K7M2in Balb/c miceEffective formulation against DOX-resistant Pgp-overexpressing OS where the rate of failure of the first-line chemotherapy is highSame cardiotoxicityprofile as Caelyx®LDL-decorated liposomes41Active:LDL receptor(via statin pre treatment)DOXPreClinical: U2OS-DX580in Balb/c miceIncreased DOX uptake.Effective reduction of tumor growth in DOX-resistant Pgp-overexpressing OSReduced DOX cardiotoxicityHLCN liposomes61Active:CD44 (HA)CDDP + siNrf2PreClinical: U2OSin Balb/c mice4x higher cytotoxicity vs liposomal CDDP (IC50 1 µM vs 4 µM)Minimal systemic toxicityLiposomal mifamurtide (L-MTP-PE)97,98Active:NOD2MTP-PEClinical use(2–30 years patients)Immunomodulator: coadministration with standard chemotherapy for the postoperative treatment of patients (2–30 years).Up to 6-year survival in non-metastatic OSEMA-approved(No FDA)10 times less toxic than MTP-PE Nanoscale Drug Delivery Systems Based on Liposomes Tested in vivo for OS Treatment Table 3Drug-Loaded Hydrogels Tested in vivo for OS TreatmentType [Ref]TargetCargoAnimal ModelEfficacySafetyBP/DOX/CS hydrogel43Local tumor siteDOXK7M2wtin Balb/c miceSynergistic photothermal chemotherapy.Phosphorus promoted bone regenerationNo systemic toxicityBPNSs-PEG-FA hydrogel44Folate receptorDOXK7M2wtin Balb/c miceSynergistic photothermal chemotherapy.pH responsiveness.Phosphorus promoted bone regenerationSafe profileSLP peptide hydrogel45Intratumoral injectionDOXK12 in Balb/c miceStrong efficacy compared to free DOXReduced off-site distributionGOMP hydrogel46Local tumor site(subcutaneous implant)DOX + PPy-PVP NPs143B in Balb/c miceSynergistic photothermal chemotherapy. Montmorillonite‑strontium (MMT-Sr) promoted bone regenerationNo side effects. In vivo degradation performance to be exploredAgarose/Fe-GA NPs hydrogel47Local tumor siteDOXK7M2wt in Balb/c miceSynergistic photothermal chemotherapy.No systemic toxicity (normal indexes of liver, kidney and blood)Ti6Al4V implant in PLGA-PEG-PLGA hydrogel63Local bone implantCDDP143B in Balb/c mice andStronger effect over the traditional systemic cisplatin delivery.Bone repair: bone in-growth and osseointegration early (4 weeks), but not later (8 weeks), after transplantation.Low systemic toxicity (negligible organ damage). Clinically approved materials: significant potential for clinical translationPLGA-PEG-PLGA hydrogel 64Local injectionDOX + CDDPHuman Saos-2 in Balb/c miceSynergistic anti-tumor efficacy of DOX and CDDPLow systemic toxicityGC-HP-β-CD hydrogel65Local injectionDOX + CDDPHuman bone KHOS/NP in Balb/c miceSynergistic effect of DOX and CDDPNo cardio-/nephrotoxicityPAMB-G-TK hydrogel loaded with Cis/Mn@Lipo-IL11 liposomes67Interleukin 11 receptor alpha (IL11Rα)CDDP + MYC inhibitor (NHWD-870)143B and K7M2 in Balb/c miceChemodynamic and immunotherapy combination. Modulation of immunesuppressive TME. Lung metastasis attenuationNo systemic toxicitymPEG45-PLV19 hydrogel77Local injectionMTX + ALNK7M2 in miceTumor suppression with minimal lung metastasis and minimal bone destruction.Well tolerated, mild transient inflammationPLGA-PEG-PLGA hydrogel78Peritumoral injectionMTX + DOX + CDDPSaos-2 in Balb/c miceHigh tumor suppression for up to 16 days, enhanced tumor apoptosis, increased regulation of apoptosis-related genes expressionNo systemic toxicityPLAF-b-PEG-b-PLAF + PLGA hydrogel81Peritumoral subcutaneous injectionDTX + CA4 (combretastatin A-4)K7M2 in Balb/c miceSynergistic effectTransient inflammation. Fully degraded after 42 days; no adverse effectsGEM-Lip@Gel hydrogel89ImplantGEMMG63- in Balb/c miceImproved antitumor effect compared to control groupsLimited inflammation.No adverse effectspBAE NPs in HA hydrogel103Peritumoral injection (hydrogel) + systemic DOXmiR-29b+ DOXK7M2 in metastatic Balb/c miceAntitumor and pro-osteogenic (normalizing bone homeostasis) dual effect. Increased survivabilitySafeCPP-chitosan coatedFe-siRad18-DOX NPsin PLGA-PEG-PLGA hydrogel110Peritumoral injectionDOX + siRad18+ PD-L1 monoclonal antibody(αPD-L1)K7M2 in Balb/c miceSynergistic gene, immuno- and chemotherapy. Enhanced ICD. Rad18 gene silencing (impeding DOX resistance).Lung metastasis mitigationNot specified Drug-Loaded Hydrogels Tested in vivo for OS Treatment Table 4Drug-Loaded Nanoparticles Tested in vivo for OS TreatmentType [Ref]TargetCargoAnimal ModelEfficacySafetyHA NPs62CD44DOX + CDDP + resiquimod (R848)K7M2 in Balb/c miceSynergistic immunochemotherapy. Lung metastasis inhibitionNo obvious organ damage or only slight organ damageAL-PtIV-Lipo NPs (PtIV prodrug)68Bisphosphonates (AL) target hydroxyapatite of boneALN + PtIVK7M2 in Balb/c miceTumor growth inhibition (TGI): 86% after 14 daysWell toleratedC16-Oxa-TEAI NPs (oxaliplatin prodrug)69Bisphosphonates (ZA) target bone microenvironment and exert vaccine adjuvant activitiesOxaliplatin + ZA in combination with PD-L1 mono antibodyK7M2 in Balb/c mice and PDXOSSynergistic chemoimmunotherapyExcellent histocompatibilityCy7-labeled Fe3O4@MSNs70CXCR1 peptide on OS circulating tumor cells (CTCs)CDDPSaos-2 in nude mice and PDXOSReduced CTC survival, tumor growth, and pulmonary metastasisNot determinedCaCO3-ICG-DDP-PEG-PT (CIDP-PT) NPs71Oligopeptide receptor-mediated targetingCDDP + ICG (NIR dye)143B in Balb/c micePhoto-chemo therapy; reduced tumor volume and burdenAbsence of structural damage to the major organsSiO₂@PDA/Fe³+-FA NPs72Folate receptorCDDPMNNG/HOS-NSC (not sensitive to cisplatin) in Balb/c miceChemodynamic and photothermal therapy (NIR irradiation)No organ toxicity (liver, lungs, and kidneys)PLGA-LDH NPs76Passive accumulationMTXHOS in Balb/c miceSignificant suppression of OS growth. Increase of survival rateNo notable body weight (systemic toxicity) changes till 40 mg/kg. Body weight decrease with ≥ 60 mg/kg. No nephro- and hepatotoxicity.PLGA-ZOL NPs87Bisphosphonates (ZA) target bone microenvironment and exert vaccine adjuvant activities.GEM + EPIMG63 in Sprague-Dawley ratsGreat efficacy in reducing tumor volume along with epigenetic changes affecting microRNA expressionsNot reportedSQ-Gem/EF NAs88Passive accumulationGEM + EF (pro-apoptotic drug)P1.15 in Balb/c miceDecreased primary tumor growth kinetics. Reduced number of lung metastasesNo significant renal/hepatic toxicity; lower neutropenia than free GEMHFn@Gem/IR-78090TfR1 receptorGEM + IR-780 (photosensitizer)K7M2 in Balb/c miceChemotherapy, photothermal, photodynamic, and chemodynamic therapyNo significant abnormalities observed in major organs and normal levels of blood biochemical markersTC/miR-22 NPs105PLK1miR-22 + VolasertibSaos-2 in nude mice, PDXOS and drug-resistant PDX modelsSuppression of tumor growth, reduction of lung metastasis risk. Overcame chemotherapy resistanceNot reportedCPCHCs NPs106PLK1siPLK1MNNG-HOS CDX in Balb/c miceSignificant tumor volume inhibitionNo toxic and side effectsPolydopamine NPs coated with stem cell membranes108STAT3siSTAT3 + curcuminMG63 in Balb/c miceExcellent antitumor effect No side effects in major organsPLGA NPs coated with mesenchymal stem cell membranes109SurvivinDOX + siSurvivinMG63 in Balb/c miceSynergistic effectNo toxicity Drug-Loaded Nanoparticles Tested in vivo for OS Treatment Table 5Drug Delivery Systems Based on Exosomes and Vesicles Tested in vivo for OS TreatmentType [Ref]TargetCargoAnimal ModelEfficacySafetyExosomes (Exo-DOX)51Active: SDF1-CXCR4 axisDOXMG63 in Balb/c miceSynergistic effect of Exo and Dox: 6-fold reduction of tumor volume at day 21 compared with free DOXReduced cardiotoxicityHybrid Exosomes (HE/DOX)52Passive: Acidic TMEDOX143B in nude miceMore successful therapeutic effect than free DOX and liposomal DOXNot evaluatedExosome Mimetics (EM/DOX)54Passive: Acidic TMEDOX143B in Balb/c miceStronger inhibitory effect compared to free DOX and liposomal DOXReduced off-target toxicityMicrovesicles derived from tumor cells (YSA-SPION-MV/MTX)79Active: EphA2 receptorMTX143B in Balb/c miceTumor weight and volume significantly reduced. Lung metastasis inhibitionNo tissue damage in major organs from histological analysis. Only minor renal tissue damageExtracellular Vesicles (EV) derived from OS cells and preosteoblasts107Active: Folate receptorHdac1-siRNA + ZAK7M2 in Balb/c miceReduce tumor burdenNo tissue damage in major organs from histological analysis Drug Delivery Systems Based on Exosomes and Vesicles Tested in vivo for OS Treatment Despite the promising results achieved in preclinical models, the transition to clinical testing in OS remains hampered by technological, physico-chemical/biological, and regulatory aspects. Specifically, translational bottlenecks of Nanotherapeutics are related to manufacturing (reproducibility, scalability, cost), long-term stability, efficacy and safety, biocompatibility, targeting ability, unconsolidated regulatory guidance, lack of predictive in vitro and in vivo models, and a lack of in vitro/in vivo correlations. For instance, Good Manufacturing Practice (GMP) challenges that delay industrial scale-up are also related to preservation of the pharmacokinetic properties observed in murine models that remain unresolved issues. In parallel, the biological heterogeneity of OS and its incidence in adolescents and young adults make it challenging to recruit statistically adequate patient cohorts, directly affecting the feasibility of randomized clinical trials. Moreover, conventional preclinical platforms (2D cell cultures and immunocompromised mouse models) fail to accurately recapitulate the human TME, particularly the heterogeneity of the human OS, the role of the bone niche in therapy response, and the interplay between systemic immune modulation and drug delivery efficiency. Specifically, subcutaneous xenografts completely lack the bone microenvironment, with vascularization and extracellular matrix markedly different from bone tissue. Orthotopic xenografts in bone better mimic the native environment but are often performed in immunodeficient mice, thus missing critical immune-bone crosstalk. While in vitro bone-mimicking systems are improving, they still cannot fully reproduce key features such as bone mineral adsorption, niche heterogeneity, and the dynamic turnover of osteoblasts and osteoclasts. From a regulatory perspective, emerging combination regimens require multi-pathway regulatory approvals and extensive safety data, including toxicity studies in higher species. Finally, economic and strategic factors restrict industrial investment in therapies targeting a limited patient population. Therefore, interdisciplinary collaborations among chemists, engineers, technologists, biologists, and clinicians could be the cornerstone to achieve technological and regulatory advancements with the goal of building scalable, safe, and truly clinically applicable therapeutic platforms aligning with individual patient profiles for optimized and personalized outcomes. Conclusion This review discusses the scientific advances of the last decade in in vivo testing of Nanotherapeutics against OS for both systemic and local delivery. Moreover, unconventional modalities like immuno- and gene therapy are also explored. Starting from the current treatment options primarily based on surgery and chemotherapy (“MAP” regimen), this comprehensive review explores emerging therapeutic approaches and suggests future directions in nanomedicine-boosted chemotherapy, immuno- and gene therapy for OS management. Although these approaches are in different stages of preclinical and/or clinical trials, they overall show promising achievement and their combination demonstrates synergistic effects and enhanced efficacy in OS treatment. Conventional chemotherapy has witnessed refined drug regimens and several drug delivery systems tailored to improve efficacy while minimizing toxicity. Moreover, combination therapy that uses more than one drug or modality appeared to be more effective than monotherapy to combat the multidrug resistance problem. Numerous nanocarriers have efficiently dealt with OS in vivo, such as liposomes, hydrogels, nanoparticles, and vesicles. Although several Nanomedicines are currently available in the market, many of the aforementioned approaches remain at the preclinical stage for OS requiring a long transitional period before clinical translation. Moreover, preclinical evaluation of these nanocarriers often lacks predictivity for human responses since traditional in vitro cell cultures do not adequately replicate the complexity of OS tumor microenvironment and animal models often fall short of mimicking the full range of tumoral conditions. Compared to other nanomaterials, liposomes represent the biggest share of Nanotherapeutics under clinical trial and they are the only delivery nanosystems already tested in phase I clinical trials in patients with metastatic and recurrent OS (ie, Pegylated liposomal doxorubicin, Duomeisu). Moreover, liposomal Mifamurtide (Mepact®, licensed by EMA since 2009) is indicated in children, adolescents and young adults (2–30 years) for the treatment of non-metastatic OS after surgical resection in combination with postoperative multi-agent chemotherapy. Furthermore, the covalent conjugation of anticancer drugs with macromolecular carriers or small molecules to form a prodrug is another strategy exploited by several authors for improving stability, prolonging retention time, and overall enhancing therapeutic efficacy. Nevertheless, only a few examples of CDDP-prodrug and GEM-prodrug have advanced in in vivo OS studies so far. The main challenge in clinical translation of prodrugs is how to maintain the biological activity after chemical modification of the structure and to guarantee the release of active free drug. Significant progress has been made in exploring the role of immune system in OS progression, including tumor microenvironment, invasion, metastasis, and immune checkpoints. Our systematic literature analysis pointed out that future trials should continue to explore combined immunotherapy-chemotherapy regimens to mark a new era in OS treatment. The landscape of gene therapy in oncology is rapidly evolving, triggered by groundbreaking advances in precision medicine and gene-editing technologies that enable highly personalized and targeted treatments. However, challenges such as OS tumor heterogeneity and immune evasion need to be addressed to exploit the full potential of gene therapy, alone or in combination with chemotherapy, for the development of patient-specific OS therapies. Overall, many challenges need to be addressed for clinical implementation of Nanotherapeutics to move them from the lab bench to the bedside. Current hurdles are related to technological, physico-chemical/biological, and regulatory challenges, including reproducibility, large-scale manufacturing, long-term stability, efficacy and safety, heterogeneity of in vitro and in vivo models, government regulations, GMP compliance, intellectual property, cost-effectiveness in comparison to current therapies, etc. Moreover, the high inter-patients variability and intra-tumoral heterogeneity of OS represent significant challenges for personalized treatment plans. Nevertheless, due to the revolutionary impact of nanotechnologies on healthcare and the plethora of positive preclinical results of the last decade for Nanotherapeutics against OS, we believe that engagement of multidisciplinary teams bridging material science, chemistry, biology, nanotechnology, translational oncology, and immunology could be key for driving both technological and regulatory advancements, aligning regulatory frameworks with science-driven standards and mitigating clinical translation.